



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 114779

TO: Rita Mitra
Location: rem/3b65
Art Unit: 1653
Friday, February 20, 2004

Case Serial Number: 09/786260

From: Barb O'Bryen
Location: Biotech-Chem Library
Remsen E01A69
Phone: 571-272-2518

barbara.obryen@uspto.gov

Search Notes

oligo search

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

protein - protein search, using sw model

February 19, 2004, 18:21:50 ; Search time 41 Seconds
(without alignments)
460.694 Million cell updates/sec

US-09-786-260-1

1 MKVLTSSLLLLPLMLSMV.....SRACQFLKQCQLRSFALPL 119

OLIGO
Gapop 60.0 , Gapext 60.0

1107863 seqs, 15876573 residues

size : 0

number of hits satisfying chosen parameters: 1107863

um DB seq length: 0

um DB seq length: 2000000000

processing: Listing first 45 summaries

ase : A.Geneseq.19Jun03.*

- 1: /SIDSI/cgdata/geneseq/geneseq-emb1/AA1980.DAT.*
- 2: /SIDSI/cgdata/geneseq/geneseq-emb1/AA1981.DAT.*
- 3: /SIDSI/cgdata/geneseq/geneseq-emb1/AA1982.DAT.*
- 4: /SIDSI/cgdata/geneseq/geneseq-emb1/AA1983.DAT.*
- 5: /SIDSI/cgdata/geneseq/geneseq-emb1/AA1984.DAT.*
- 6: /SIDSI/cgdata/geneseq/geneseq-emb1/AA1985.DAT.*
- 7: /SIDSI/cgdata/geneseq/geneseq-emb1/AA1986.DAT.*
- 8: /SIDSI/cgdata/geneseq/geneseq-emb1/AA1987.DAT.*
- 9: /SIDSI/cgdata/geneseq/geneseq-emb1/AA1988.DAT.*
- 10: /SIDSI/cgdata/geneseq/geneseq-emb1/AA1989.DAT.*
- 11: /SIDSI/cgdata/geneseq/geneseq-emb1/AA1990.DAT.*
- 12: /SIDSI/cgdata/geneseq/geneseq-emb1/AA1991.DAT.*
- 13: /SIDSI/cgdata/geneseq/geneseq-emb1/AA1992.DAT.*
- 14: /SIDSI/cgdata/geneseq/geneseq-emb1/AA1993.DAT.*
- 15: /SIDSI/cgdata/geneseq/geneseq-emb1/AA1994.DAT.*
- 16: /SIDSI/cgdata/geneseq/geneseq-emb1/AA1995.DAT.*
- 17: /SIDSI/cgdata/geneseq/geneseq-emb1/AA1996.DAT.*
- 18: /SIDSI/cgdata/geneseq/geneseq-emb1/AA1997.DAT.*
- 19: /SIDSI/cgdata/geneseq/geneseq-emb1/AA1998.DAT.*
- 20: /SIDSI/cgdata/geneseq/geneseq-emb1/AA1999.DAT.*
- 21: /SIDSI/cgdata/geneseq/geneseq-emb1/AA2000.DAT.*
- 22: /SIDSI/cgdata/geneseq/geneseq-emb1/AA2001.DAT.*
- 23: /SIDSI/cgdata/geneseq/geneseq-emb1/AA2002.DAT.*
- 24: /SIDSI/cgdata/geneseq/geneseq-emb1/AA2003.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

lt	Score	Match	Length	ID	Description
1	119	100.0	119	21	Human secreted pro
2	119	100.0	119	21	Human TGC-440 secr
3	119	100.0	119	21	Human signal pepti
4	119	100.0	119	21	Membrane-bound pro
5	119	100.0	119	22	Human PRO polypept
6	119	100.0	119	22	Amino acid sequenc
7	119	100.0	119	22	Human PRO842. Hom
8	119	100.0	119	22	Human PRO842 (UNQ4
9	119	100.0	119	23	Human cytokine PRO

10	119	100.0	119	23	ABG55863	Human secreted/tra
11	119	100.0	119	24	ABU71181	Human PRO842 prote
12	119	100.0	119	24	ABU71518	Human secreted pol
13	119	100.0	119	24	ABU71964	Novel human secret
14	119	100.0	119	24	ABU72121	Human PRO polypept
15	119	100.0	119	24	ABU65638	Human secreted/tra
16	119	100.0	119	24	ABU65971	Novel human secret
17	119	100.0	119	24	ABU67475	Human secreted/tra
18	119	100.0	119	24	ABU65333	Human PRO polypept
19	119	100.0	119	24	ABU59084	Novel human secret
20	119	100.0	119	24	ABU59231	Human secreted/tra
21	119	100.0	119	24	ABU59380	Novel human secret
22	119	100.0	119	24	ABU60515	Human secreted/tra
23	119	100.0	119	24	ABU58006	Human PRO polypept
24	119	100.0	119	24	ABU58469	Human PRO polypept
25	119	100.0	119	24	ABU58937	Human secreted/tr
26	119	100.0	119	24	ABU56005	Human secreted/tra
27	119	100.0	119	24	ABU57000	Human PRO polypept
28	119	100.0	119	24	ABU13897	Human PRO842 polyp
29	119	100.0	119	24	ABU10579	Human secreted/tra
30	119	100.0	119	24	ABU10852	Human PRO polypept
31	97	81.5	97	21	AAV82454	Mature human TGC-4
32	93	78.2	93	19	AAW83953	Polypeptide encode
33	69	58.0	69	20	AAV11732	Human 5' EST secre
34	64	54.0	64	19	AAW63938	Human secreted PRO
35	24	20.2	48	20	AAV11731	Human 5' EST secre
36	13	10.9	97	21	AAV82458	Mature mouse TGC-4
37	13	10.9	119	21	AAV82457	Mouse TGC-440 secr
38	9	7.6	144	21	AAW09686	Arabidopsis thalia
39	8	6.7	58	22	AAU22441	Human cardiovascu
40	8	6.7	60	22	ABG57426	Human liver peptid
41	8	6.7	60	22	ABW41994	Peptide #9500 enco
42	8	6.7	60	22	ABW25625	Protein #7624 enco
43	8	6.7	60	22	ABW28872	Human brain expres
44	8	6.7	60	22	AAW55685	Human bone marrow
45	8	6.7	60	22	AAW35795	Peptide #9832 enco

ALIGNMENTS

RESULT 1

ABW34728
ID AAB34728 standard; Protein; 119 AA.

XX AAB34728;

XX 26-JAN-2001 (first entry)

XX Human secreted protein encoded by DNA clone vq8 1.

Secreted protein; human; autoimmune disorder; multiple sclerosis; ulcer; systemic lupus erythematosus; rheumatoid arthritis; anaemia; stroke; hematopoiesis regulation; tissue regrowth; wound healing; haemophilia; Alzheimer's disease; Parkinson's disease; Shy-drager syndrome; cancer; contraceptive; infection; growth inhibition; hyperproliferative disorder; psoriasis.

XX Homo sapiens.

XX WO20005375-A1.

XX 21-SEP-2000.

XX 17-MAR-2000; 2000MO-US07285.

XX 17-MAR-1999; 99US-0124808.

XX 17-MAR-1999; 99US-0124916.

XX 17-AUG-1999; 99US-0149639.

XX 01-OCT-1999; 99US-0157247.

XX 29-NOV-1999; 99US-0167824.

XX 15-FEB-2000; 2000US-0182711.

(ALPH-) ALPHAGE INC.

Valenzuela D, Yuan O, Hoffman H, Hall J, Rapiejko P;

WPI; 2000-638211/61.
N-PSDB; AAC59829.

Novel proteins and polypeptides useful for the treatment of e.g multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, cancer, Alzheimer's disease, Parkinson's disease, stroke, anemia and ulcers

Claim 92; Page 441-442; 493pp; English.

This invention relates to 59 human secreted proteins and the nucleotide sequences encoding them. Sequences AAC59788-C59846 and AAB34687-B34745 represent the proteins and their encoding nucleotide sequences, and sequences AAB34746-B34771 represent fragments of the proteins. Probes for the DNA sequences are represented by sequences AAC59847-C59896. The proteins exhibit neuroprotective, dermatological, immunosuppressive, anti-inflammatory, antianemic, neurotropic, antiparkinsonian, cerebroprotective, haemostatic, vulnerable, cytostatic, antiproliferative, antibacterial, virucide, and fungicide activity. The proteins and nucleotide sequences are useful as nutritional sources or supplements and in research. The proteins are useful for treating immune deficiency and disorders which may be genetic or resulting from infections, autoimmune disorders such as multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, and for treating myeloid or lymphoid cell deficiencies such as anaemias by regulating haemopoiesis. The proteins are also useful in compositions for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, for wound healing, tissue repair and replacement and in the treatment of central and ulcers. Other uses include in the treatment of central and peripheral nervous system and neuropathies such as Alzheimer's and Parkinson's diseases and Shy-Drager syndrome, and mechanical and traumatic disorders, such as spinal cord disorders, head trauma and stroke. The proteins may also be used as a contraceptive, and for treating coagulation disorders such as haemophilias. The protein and nucleotide sequences with cadherin activity are useful for treating cancer. Other uses for the protein include for inhibiting the growth, infection or function of, or killing, infectious agents such as bacteria, virus, fungi and other parasites, for effecting bodily characteristics such as height, weight, hair colour, effecting biorythms or cardiac cycles or rhythms, effecting metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors, effecting behavioural characteristics, providing analgesic effects and for treating hyperproliferative disorders such as psoriasis.

Sequence 119 AA;

Query Match 100.0%; Score 119; DB 21; Length 119;
Best Local Similarity 100.0%; Pred. No. 3.3e-110;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
1 MKVLISLLLLPLMLSMVSSSLNPGVARGHRRDQAGRRMLQEGGQCECKDWFLRAP 60
1 MKVLISLLLLPLMLSMVSSSLNPGVARGHRRDQAGRRMLQEGGQCECKDWFLRAP 60
61 RKKFTVSGLPKQPCDHPKGNVKKTRHQRHRRKPKNGKSRACQQLKQCLRSFALPL 119
61 RKKFTVSGLPKQPCDHPKGNVKKTRHQRHRRKPKNGKSRACQQLKQCLRSFALPL 119

ULT 2
82453

AA582453 standard; Protein; 119 AA.

AA582453;

30-JUN-2000 (first entry)

Human TGC-440 secretory protein SEQ ID NO:1.

XX TGC-440; secretory protein; immunological disease; infectious disease;
KW pulmonary function disorder; hepatic function disorder; nephrotropic;
KW gastrointestinal function disorder; anti-inflammatory; immunomodulatory;
KW virucide; hepatotropic; antiasthmatic; antibacterial; vaccine;
KW hepatitis; nephritis; influenza; asthma; pulmonary hypertension;
KW pneumonia; Helicobacter pylori infection.

OS Homo sapiens.

XX WO200014226-A1.

XX 16-MAR-2000.

XX 02-SEP-1999; 99WO-JP04765.

XX 03-SEP-1998; 98JP-0250108.

XX (TAKA) TAKEDA CHEM IND LTD.

XX Itoh Y, Ogi K, Tanaka H, Kitada C;

XX WPI; 2000-256978/22.

XX N-PSDB; AAA08343, AAA08344.

XX Secretory protein TGC440, antibodies to it and compounds promoting or
PT inhibiting its activity for diagnosis and treatment of diseases of the
PT immune system, lung, kidney, liver and intestinal system

XX Claim 1; Fig 1; 86pp; Japanese.

XX The present sequence represents a human secretory protein designated
CC TGC-440. TGC-440 has anti-inflammatory, nephrotropic, immunomodulatory,
CC virucide, hepatotropic, antiasthmatic and antibacterial activities,
CC and can be used in vaccines. TGC-440 and the polynucleotide sequence
CC encoding it can be used to treat, prevent and diagnose immunological,
CC lung, liver, kidney or gastrointestinal disorders and infectious
CC diseases, such as hepatitis, nephritis, influenza, asthma, pneumonia,
CC pulmonary hypertension, and Helicobacter pylori infection. An antibody
CC immunospecific for TGC-440 is also useful in the above treatment and
CC diagnosis, and also for quantifying the amount of TGC-440 in a liquid
CC specimen.

XX Sequence 119 AA;

Query Match 100.0%; Score 119; DB 21; Length 119;
Best Local Similarity 100.0%; Pred. No. 3.3e-110;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MKVLISLLLLPLMLSMVSSSLNPGVARGHRRDQAGRRMLQEGGQCECKDWFLRAP 60
Db 1 MKVLISLLLLPLMLSMVSSSLNPGVARGHRRDQAGRRMLQEGGQCECKDWFLRAP 60
QY 61 RKKFTVSGLPKQPCDHPKGNVKKTRHQRHRRKPKNGKSRACQQLKQCLRSFALPL 119
Db 61 RKKFTVSGLPKQPCDHPKGNVKKTRHQRHRRKPKNGKSRACQQLKQCLRSFALPL 119

RESULT 3

AA587317

ID AA587317 standard; Protein; 119 AA.

XX AA587317;

XX 11-MAY-2000 (first entry)

XX Human signal peptide containing protein HSPP-94 SEQ ID NO:94.

XX Human; signal peptide-containing protein; HSPP; diagnosis; cancer;
KW inflammation; cardiovascular disease; anticancer; anti-inflammatory;
KW antimicrobial; neuroprotective; cardiovascular; hepatotropic;
KW antiasthmatic; gene therapy; cell proliferation; neurological disorder;
KW reproductive disorder; developmental disorder; arteriosclerosis;

irrhosis; psoriasis; acquired immune deficiency syndrome; anaemia; asthma; Crohn's disease; infection; Alzheimer's disease; schizophrenia; Parkinson's disease; Huntington's diseases; ovulatory defect; muscular dystrophy.

homo sapiens.

02000000610-A2.

16-JAN-2000.

15-JUN-1999; 99WO-US14484.

16-JUN-1998; 98US-0090762.

11-JUL-1998; 98US-0094983.

11-OCT-1998; 98US-0102686.

11-DEC-1998; 98US-0112129.

(INCY-) INCYTE PHARM INC.

Lal P, Tang YT, Gorgone GA, Corley NC, Guegler KJ, Baughn MR; Akerblom IE, Au-Young J, Yue H, Patterson C, Reddy R, Hillman JL; Bandman O;

WPI; 2000-160673/14.

N-PSDB; AA298202.

New human signal peptide-containing proteins useful in treatment, prevention and diagnosis of e.g. cancer, inflammation and cardiovascular disease -

Claim 1; Page 220-221; 327pp; English.

AAZ98109 to AAZ98242 encode AY87224 to AY87357 which represent the human signal peptide-containing proteins HSPP-1 to HSPP-134. HSPPs have anticancer, anti-inflammatory, antimicrobial, neurotropic, hepatotropic, neuroprotective, cardiovascular and antiasthmatic activities, and can be used in gene therapy. HSPPs can be used to treat or prevent disorders associated with decreased activity or function of HSPP. Antagonists of HSPP are used to treat or prevent disorders associated with increased activity or function of HSPP. Such diseases include cell proliferation (including cancer), inflammation, cardiovascular, neurological, reproductive or developmental disorders, (e.g. arteriosclerosis, cirrhosis, psoriasis, acquired immune deficiency syndrome, anaemia, asthma, Crohn's disease, microbial or other infections, congestive or ischaemic heart disease, Alzheimer's, Parkinson's or Huntington's diseases, schizophrenia, ovulatory defects, muscular dystrophy). HSPP nucleic acids can be used for the recombinant production of HSPP, for detecting HSPP in standard hybridisation and amplification assays (for diagnosis and monitoring), in gene therapy, as antisense, triplex-forming or ribozyme therapeutics, for detecting related sequences or genetic variations, and for chromosomal mapping. HSPP are also used to raise specific antibodies (Ab) and to screen for agonists and antagonists (potential therapeutic agents). Ab are used to diagnose, or monitor, HSPP-related diseases (in usual immunoassays), as therapeutic antagonists, in competitive drug screens, and for purification of HSPP from natural sources.

Sequence 119 AA;

100.0%; Score 119; DB 21; Length 119;
Local Similarity 100.0%; Pred. No. 3,3e-110;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 MKVLSLSLLPLMLMSVSSNPGVAGHRRDRCQASHRWLQEGQCECKDWFLAP 60

1 MKVLSLSLLPLMLMSVSSNPGVAGHRRDRCQASHRWLQEGQCECKDWFLAP 60

61 RKKFTVTSGLPKQCPDHFHKGYNKTKTHQRHHRKPNKHSRAQQQLKQCLRSFALPL 119

61 RKKFTVTSGLPKQCPDHFHKGYNKTKTHQRHHRKPNKHSRAQQQLKQCLRSFALPL 119

RESULT 4

AAZ98109

ID AAY66668 standard; protein; 119 AA.

XX AC AAY66668;

XX XX

DT 05-APR-2000 (first entry)

XX XX Membrane-bound protein PRO842.

KW KW Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand;

XX KW pharmaceutical; receptor immunoadhesin; gene mapping.

XX XX Homo sapiens.

PN WO9963088-A2.

XX PD 09-DEC-1999.

XX XX 02-JUN-1999; 99WO-US12252.

XX XX 02-JUN-1998; 98US-0087607.

PR 02-JUN-1998; 98US-0087609.

PR 02-JUN-1998; 98US-0087759.

PR 03-JUN-1998; 98US-0087827.

PR 04-JUN-1998; 98US-0088021.

PR 04-JUN-1998; 98US-0088025.

PR 04-JUN-1998; 98US-0088028.

PR 04-JUN-1998; 98US-0088029.

PR 04-JUN-1998; 98US-0088030.

PR 04-JUN-1998; 98US-0088033.

PR 04-JUN-1998; 98US-0088326.

PR 05-JUN-1998; 98US-0088167.

PR 05-JUN-1998; 98US-0088202.

PR 05-JUN-1998; 98US-0088212.

PR 05-JUN-1998; 98US-0088217.

PR 09-JUN-1998; 98US-0088655.

PR 10-JUN-1998; 98US-0088722.

PR 10-JUN-1998; 98US-0088730.

PR 10-JUN-1998; 98US-0088734.

PR 10-JUN-1998; 98US-0088738.

PR 10-JUN-1998; 98US-0088740.

PR 10-JUN-1998; 98US-0088741.

PR 10-JUN-1998; 98US-0088742.

PR 10-JUN-1998; 98US-0088810.

PR 10-JUN-1998; 98US-0088811.

PR 10-JUN-1998; 98US-0088824.

PR 10-JUN-1998; 98US-0088825.

PR 10-JUN-1998; 98US-0088826.

PR 11-JUN-1998; 98US-0088858.

PR 11-JUN-1998; 98US-0088859.

PR 11-JUN-1998; 98US-0088861.

PR 11-JUN-1998; 98US-0088863.

PR 11-JUN-1998; 98US-0088876.

PR 12-JUN-1998; 98US-0089090.

PR 12-JUN-1998; 98US-0089105.

PR 15-JUN-1998; 98US-0089440.

PR 16-JUN-1998; 98US-0089512.

PR 16-JUN-1998; 98US-0089514.

PR 17-JUN-1998; 98US-0089532.

PR 17-JUN-1998; 98US-0089538.

PR 17-JUN-1998; 98US-0089598.

PR 17-JUN-1998; 98US-0089599.

PR 17-JUN-1998; 98US-0089600.

PR 17-JUN-1998; 98US-0089653.

PR 18-JUN-1998; 98US-0089801.

PR 18-JUN-1998; 98US-0089907.

PR 18-JUN-1998; 98US-0089908.

PR 19-JUN-1998; 98US-0089947.

PR 19-JUN-1998; 98US-0089948.

PR 19-JUN-1998; 98US-0089952.

PR 22-JUN-1998; 98US-0090246.

PR 22-JUN-1998; 98US-0090252.

PR 22-JUN-1998; 98US-0090254.

```

23-JUN-1998; 98US-0090349.
23-JUN-1998; 98US-0090355.
24-JUN-1998; 98US-0090429.
24-JUN-1998; 98US-0090431.
24-JUN-1998; 98US-0090435.
24-JUN-1998; 98US-0090444.
24-JUN-1998; 98US-0090445.
24-JUN-1998; 98US-0090461.
24-JUN-1998; 98US-0090472.
24-JUN-1998; 98US-0090535.
24-JUN-1998; 98US-0090538.
24-JUN-1998; 98US-0090540.
24-JUN-1998; 98US-0090557.
25-JUN-1998; 98US-0090676.
25-JUN-1998; 98US-0090678.
25-JUN-1998; 98US-0090688.
25-JUN-1998; 98US-0090690.
25-JUN-1998; 98US-0090691.
25-JUN-1998; 98US-0090694.
25-JUN-1998; 98US-0090695.
25-JUN-1998; 98US-0090696.
26-JUN-1998; 98US-0090862.
26-JUN-1998; 98US-0090863.
01-JUL-1998; 98US-0091389.
01-JUL-1998; 98US-0091390.
01-JUL-1998; 98US-0091544.
02-JUL-1998; 98US-0091478.
02-JUL-1998; 98US-0091486.
02-JUL-1998; 98US-0091519.
02-JUL-1998; 98US-0091626.
02-JUL-1998; 98US-0091628.
02-JUL-1998; 98US-0091633.
02-JUL-1998; 98US-0091646.
02-JUL-1998; 98US-0091673.
07-JUL-1998; 98US-0091978.
07-JUL-1998; 98US-0091982.
09-JUL-1998; 98US-0092182.
10-JUL-1998; 98US-0092472.
20-JUL-1998; 98US-0093339.
30-JUL-1998; 98US-0094651.
04-AUG-1998; 98US-0095282.
04-AUG-1998; 98US-0095285.
04-AUG-1998; 98US-0095301.
04-AUG-1998; 98US-0095302.
04-AUG-1998; 98US-0095318.
04-AUG-1998; 98US-0095321.
04-AUG-1998; 98US-0095325.
10-AUG-1998; 98US-0095916.
10-AUG-1998; 98US-0095929.
10-AUG-1998; 98US-0096012.
11-AUG-1998; 98US-0096143.
11-AUG-1998; 98US-0096146.
12-AUG-1998; 98US-0096329.
17-AUG-1998; 98US-0096757.
17-AUG-1998; 98US-0096766.
17-AUG-1998; 98US-0096768.
17-AUG-1998; 98US-0096773.
17-AUG-1998; 98US-0096791.
17-AUG-1998; 98US-0096867.
17-AUG-1998; 98US-0096881.
17-AUG-1998; 98US-0096884.
17-AUG-1998; 98US-0096895.
17-AUG-1998; 98US-0096897.
18-AUG-1998; 98US-0096949.
18-AUG-1998; 98US-0096950.
18-AUG-1998; 98US-0096959.
18-AUG-1998; 98US-0096960.
18-AUG-1998; 98US-0097022.
19-AUG-1998; 98US-0097141.
20-AUG-1998; 98US-0097218.
24-AUG-1998; 98US-0097561.
26-AUG-1998; 98US-0097951.
26-AUG-1998; 98US-0097952.

26-AUG-1998; 98US-0097954.
26-AUG-1998; 98US-0097955.
26-AUG-1998; 98US-0097971.
26-AUG-1998; 98US-0097974.
26-AUG-1998; 98US-0097978.
26-AUG-1998; 98US-0097979.
26-AUG-1998; 98US-0097986.
26-AUG-1998; 98US-0097986.
26-AUG-1998; 98US-0098014.
31-AUG-1998; 98US-0098525.
PR 16-SEP-1998; 98US-0100634.
PR 12-JAN-1999; 99US-0115565.
XX
XX (GETH ) GENENTECH INC.
XX Baker K, Chen J, Goddard A, Gurney AL, Smith V, Watanabe CK,
PI Wood WI, Yuan J;
XX WPI; 2000-072883/06.
XX N-PSDB; AAZ65001.
XX Membrane-bound proteins and related nucleotide sequences -
XX claim 12; Fig 99; 822pp; English.
XX
XX The invention provides membrane-bound PRO polypeptides and
CC polynucleotides encoding them. The PRO sequences of the invention were
CC identified based on extracellular domain homology screening. The PRO
CC sequences have homology with proteins including LDL receptors, TIE
CC ligands and various enzymes. The membrane-bound proteins and receptor
CC molecules are useful as pharmaceutical and diagnostic agents. Receptor
CC immunoadhesins, for instance, can be used as therapeutic agents to block
CC receptor-ligand interactions. The membrane-bound proteins can also be
CC employed for screening of potential peptide or small molecule inhibitors
CC of the relevant receptor/ligand interaction. The PRO encoding sequences
CC are useful as hybridization probes, in chromosome and gene mapping and in
CC the generation of antisense RNA and DNA. PRO nucleic acid sequences
CC will also be useful for the preparation of PRO polypeptides, especially
CC by recombinant techniques.
XX
XX Sequence 119 AA:
SQ
Query Match 100.0%; Score 119; DB 21; Length 119;
Best Local Similarity 100.0%; Pred. No. 3.3e-110;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHEDRQASRRWLQEGGQCECKDWFLRAP 60
Db 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHEDRQASRRWLQEGGQCECKDWFLRAP 60
QY 61 RKFWTVSGLPKQPCDHPKGNVYKTRQHRHKKHKSACQOPLKQQLRSFALPL 119
Db 61 RKFWTVSGLPKQPCDHPKGNVYKTRQHRHKKHKSACQOPLKQQLRSFALPL 119
RESULT 5
AAU29093
ID AAU29093 standard; Protein; 119 AA.
XX
XX AAU29093;
AC AAU29093;
XX
DT 18-DEC-2001 (first entry)
XX
XX Human PRO polypeptide sequence #70.
XX
XX PRO polypeptide; mammal; tumour; cancer; human; cattle; horse; sheep;
KW dog; cat; pig; goat; rabbit; tumour necrosis factor alpha; TNF-alpha;
KW blood; chondrocyte cell; cell proliferation; cell differentiation; colon;
KW adrenal; lung; breast; prostate; rectum; cervix; liver; genetic disorder.
XX
XX Homo sapiens.
XX
XX WO200168848-A2.
XX

```

0-SEP-2001.

8-FEB-2001; 2001WO-US06520.

1-MAR-2000; 2000WO-US05601.
2-MAR-2000; 2000WO-US05841.
3-MAR-2000; 2000US-187202P.
6-MAR-2000; 2000US-186969P.
4-MAR-2000; 2000US-189320P.
4-MAR-2000; 2000US-189328P.
5-MAR-2000; 2000WO-US06884.
1-MAR-2000; 2000US-190828P.
1-MAR-2000; 2000US-191007P.
1-MAR-2000; 2000US-191048P.
1-MAR-2000; 2000US-191314P.
8-MAR-2000; 2000US-192655P.
9-MAR-2000; 2000US-193032P.
9-MAR-2000; 2000US-193053P.
0-MAR-2000; 2000WO-US08439.
4-APR-2000; 2000US-194449P.
4-APR-2000; 2000US-194647P.
1-APR-2000; 2000US-195975P.
1-APR-2000; 2000US-196000P.
1-APR-2000; 2000US-196187P.
1-APR-2000; 2000US-196890P.
1-APR-2000; 2000US-196820P.
8-APR-2000; 2000US-198121P.
5-APR-2000; 2000US-198585P.
5-APR-2000; 2000US-199397P.
5-APR-2000; 2000US-199550P.
5-APR-2000; 2000US-199654P.
13-MAY-2000; 2000US-201516P.
7-MAY-2000; 2000WO-US1370S.
12-MAY-2000; 2000WO-US14042.
0-MAY-2000; 2000WO-US14941.
12-JUN-2000; 2000WO-US15264.
15-JUN-2000; 2000US-209832P.
8-JUL-2000; 2000WO-US20710.
12-AUG-2000; 2000US-0644848.
14-AUG-2000; 2000WO-US23328.
18-NOV-2000; 2000WO-US30952.
1-DEC-2000; 2000WO-US32678.
10-DEC-2000; 2000WO-US34956.

(GETH) GENENTECH INC.

Jaker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;

WPI; 2001-602746/68.

N-PSDB; AAS45994.

Novel nucleic acids encoding PRO polypeptides, used to diagnose the presence of tumours, such as prostate and breast tumours, in mammals and to screen for modulators of the compounds -

Claim 11; Fig 140; 774pp; English.

Sequences AU29024-AU29328 represent PRO polypeptides of the invention. The PRO polypeptides and their associated nucleic acids can be used to detect the presence of a tumour in a mammal by comparing the level of expression of a PRO polypeptide in a test sample of cells from the animal and a control sample of normal cells, whereby a higher level of expression in the test sample indicates the presence of a tumour in the animal. Mammals include dogs, cats, cattle, horses, sheep, pigs, goats and rabbits but are preferably human. The polypeptides can be used to stimulate tumour necrosis factor (TNF) alpha release from human blood, when contacted with it. A specific polypeptide can be used to stimulate the proliferation or differentiation of chondrocyte cells. The PRO proteins can be used to determine the presence of tumours and also susceptibility to tumour development, particularly adrenal, lung, colon, breast, prostate, rectal, cervical, or liver tumours, in mammalian subjects. The oligonucleotide probes specific for the PRO nucleic acids

CC can be used for genetic analysis of individuals with genetic disorders.

XX Sequence 119 AA;
SQ Query Match 100.0%; Score 119; DB 22; Length 119;
Best Local Similarity 100.0%; Pred. No. 3.3e-110;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MKVLISLLLLLPLMLMSVSSSLNPGVARGHRDRGQASRRWLQGGQCECKDWFLRAP 60
Db 1 MKVLISLLLLLPLMLMSVSSSLNPGVARGHRDRGQASRRWLQGGQCECKDWFLRAP 60
QY 61 RRKFTVSGLPKQPCDHFKNVKTTRHRRHKNKSRACQOFLKQQLRSFALPL 119
Db 61 RRKFTVSGLPKQPCDHFKNVKTTRHRRHKNKSRACQOFLKQQLRSFALPL 119
RESULT 6
AAG63977
ID AAG63977 standard; Protein; 119 AA.
XX
AC AAG63977;
XX
DT 13-NOV-2001 (first entry)
XX Amino acid sequence of a human Lng104 polypeptide.
XX Human; lung cancer specific gene; LSG; Lng104; lung cancer.
XX Homo sapiens.
XX WO200161055-A2.
XX 23-AUG-2001.
XX 20-FEB-2001; 2001WO-US05674.
XX 17-FEB-2000; 2000US-0183188.
XX (DIAD-) DIADEXUS INC.
XX Chen S, Sun Y, Macina RA;
PI WPI; 2001-529917/58.
DR N-PSDB; AAG77949, AAG77951.
XX
PT New lung cancer specific gene for the treatment and diagnosis of lung cancer -
PS Claim 2; Page 115-116; 119pp; English.
XX
CC The present sequence is encoded by a human lung cancer specific gene (LSG), and represents a polypeptide designated Lng104. LSGs are useful in the treatment and diagnosis of lung cancer. The treatment of lung cancer comprises the administration of a molecule which down regulates the expression of an LSG. An immune response can be mounted against a target cell expressing an LSG. Identification of potential therapeutic agents for use in imaging and treating lung cancer which comprises screening molecules for an ability to bind to or decrease expression of an LSG relative to LSG in the absence of the agent where the ability of a molecule to bind to the LSG or decrease expression of the LSG is indicative of the molecule being useful in imaging and treating lung cancer.
XX Sequence 119 AA;
SQ Query Match 100.0%; Score 119; DB 22; Length 119;
Best Local Similarity 100.0%; Pred. No. 3.3e-110;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MKVLISLLLLLPLMLMSVSSSLNPGVARGHRDRGQASRRWLQGGQCECKDWFLRAP 60
Db 1 MKVLISLLLLLPLMLMSVSSSLNPGVARGHRDRGQASRRWLQGGQCECKDWFLRAP 60

sequences, and their fragments, can be used as hybridisation probes, in chromosomal and gene mapping, and in the generation of anti-sense RNA and DNA. They may also be used to produce transgenic animals which are used to develop and screen therapeutically useful reagents. The PRO nucleotide and protein sequence can be used for tissue typing and in reagent cancer. Anti-PRO antibodies can be used in diagnostic assays. AP44270 to AAP44470 represent PCR primers and hybridisation probes used in the isolation of human PRO sequences. AAP44087 to AAP44269 and AB65154 to AAB65300 represent human PRO polynucleotide and protein sequences given in the exemplification of the present invention.

sequence 119 AA;
Y Match 100.0%; Score 119; DB 22; Length 119;
Local Similarity 100.0%; Pred. No. 3.3e-110;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDRGQASRWLQGGQCECKDWFRLAP 60
1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDRGQASRWLQGGQCECKDWFRLAP 60
61 RRKFMTVSLPKKQCPCHDFKGNVKTTHQHHKPKNKHSPACQOFLKQCLRSFALPL 119
61 RRKFMTVSLPKKQCPCHDFKGNVKTTHQHHKPKNKHSPACQOFLKQCLRSFALPL 119

9
331
ABP54931 standard; Protein; 119 AA.
ABP54931;
08-JAN-2003 (first entry)
human cytokine PRO842 (CK27).
PRO842; CK27; chemokine; human; antiinflammatory; dermatological;
hepatotropic; antiallergic; antiasthmatic; immunosuppressive;
antithyroid; antidiabetic; antianemic; haemostatic; antipsoriatic;
antirheumatic; antiarthritic; nephrotropic.

Homo sapiens.
Key Location/Qualifiers
Peptide 1..22
Protein /label= Signal_peptide
23..119
Modified-site /label= Mature_protein
27..32
Modified-site /note= "potential N-myristoylation site"
39..41
Modified-site /note= "potential protein kinase C phosphorylation site"
46..51
Modified-site /note= "potential N-myristoylation site"

W0200270706-A2.
12-SEP-2002.
07-DEC-2001; 2001WO-US48060.
28-FEB-2001; 2001WO-US06520.
28-AUG-2001; 2001US-0941992.
(GETH) GENENTECH INC.
French D, Grimaldi JC, Hilian KJ, Pisabarro MT, Schmidt KN;
Smith V, Tumas D, Vandlen RL, Watanabe CK, Williams PW, Wood WI;
WPI; 2002-750461/81.
N-FSDB; ABV73914.

PT New PRO842 polypeptides having structural homology to interleukin-8,
PI useful for treating or diagnosing a mammal with an inflammatory disease
PI or immune related disease, e.g. rheumatoid arthritis, osteoarthritis or
PI allergic disease -
XX
XX
XX

Claim 1; Fig 2; 118pp; English.

CC The present sequence is the protein sequence of PRO842 (CK27),
CC a novel human chemokine (mol.wt. 13.8 kDa, pI 11.16) having
CC structural homology to interleukin-8. Microarray analysis has
CC shown PRO842 to be over-expressed in colon tumour, lung tumour and
CC breast tumour cells compared with non-cancerous human tissue,
CC making it a useful diagnostic marker for cancerous tumours and a
CC therapeutic target. PRO842 also plays a role in the inflammatory
CC response, having chemoattractant properties toward monocytes and
CC dendritic cells. The invention provides PRO842 polypeptides,
CC polynucleotides, host cells, vectors and antibodies, as well as
CC methods of treating an immune related disorder by using a PRO842
CC polypeptide, or an agonist, antagonist or antibody. The immune
CC related disorder may be systemic lupus erythematosus, rheumatoid
CC arthritis, osteoarthritis, juvenile chronic arthritis,
CC spondyloarthritis, systemic sclerosis, idiopathic inflammatory
CC myopathy, Sjogren's syndrome, systemic vasculitis, sarcoidosis,
CC autoimmune haemolytic anaemia, autoimmune thrombocytopaenia,
CC thyroiditis, diabetes mellitus, immune-mediated renal disease,
CC demyelinating disease of the central or peripheral nervous system,
CC idiopathic demyelinating polyneuropathy, Guillain-Barre syndrome,
CC chronic inflammatory demyelinating polyneuropathy, hepatobiliary
CC disease, infectious or autoimmune chronic active hepatitis, primary
CC biliary cirrhosis, granulomatous hepatitis, sclerosing cholangitis,
CC inflammatory bowel disease, gluten-sensitive enteropathy, Whipple's
CC disease, an autoimmune or immune-mediated skin disease, a bullous
CC skin disease, erythema multiforme, contact dermatitis, psoriasis,
CC an allergic disease, asthma, allergic rhinitis, atopic dermatitis,
CC food hypersensitivity, urticaria, an immunologic disease of the
CC ovaries, an immunologic disease of the lung, eosinophilic
CC pneumonia, idiopathic pulmonary fibrosis, hypersensitivity
CC pneumonitis, a transplantation associated disease, graft rejection
CC or graft-versus-host-disease (all claimed).
XX Sequence 119 AA;

Query Match 100.0%; Score 119; DB 23; Length 119;
Best Local Similarity 100.0%; Pred. No. 3.3e-110;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDRGQASRWLQGGQCECKDWFRLAP 60
DB 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDRGQASRWLQGGQCECKDWFRLAP 60
QY 61 RRKFMTVSLPKKQCPCHDFKGNVKTTHQHHKPKNKHSPACQOFLKQCLRSFALPL 119
DB 61 RRKFMTVSLPKKQCPCHDFKGNVKTTHQHHKPKNKHSPACQOFLKQCLRSFALPL 119

RESULT 10
ABG95863
ID ABG95863 standard; Protein; 119 AA.
XX
XX
AC ABG95863;
XX
DT 10-DEC-2002 (first entry)
XX
DE Human secreted/transmembrane protein PRO842.
XX Human; secreted protein; transmembrane protein; antirheumatic;
KW antiarthritic; osteopathic; sports-related joint problem;
KW articular cartilage defect; osteoarthritis; rheumatoid arthritis.
XX Homo sapiens.
XX OS
XX US2002119130-A1.
XX

29-AUG-2002.
06-DEC-2001; 2001US-0006867.
29-OCT-1997; 97US-063435P.
29-OCT-1997; 97US-064215P.
22-APR-1998; 98US-082797P.
29-APR-1998; 98US-083495P.
15-MAY-1998; 98US-085579P.
10-JUN-1998; 98US-088811P.
10-JUN-1998; 98US-088824P.
10-JUN-1998; 98US-088825P.
11-JUN-1998; 98US-088863P.
12-JUN-1998; 98US-089105P.
16-JUN-1998; 98US-089514P.
16-SEP-1998; 98US-089513P.
08-MAR-1999; 99WO-US05028.
14-MAY-1999; 99WO-US10733.
02-JUN-1999; 99WO-US12252.
01-SEP-1999; 99WO-US20111.
15-SEP-1999; 99WO-US21090.
15-SEP-1999; 99WO-US21134.
22-DEC-1999; 99WO-US30720.
18-FEB-2000; 2000WO-US04341.
18-FEB-2000; 2000WO-US04342.
30-MAR-2000; 2000WO-US08439.
22-MAY-2000; 2000WO-US14042.
02-JUN-2000; 2000WO-US15284.
23-AUG-2000; 2000WO-US23522.
24-AUG-2000; 2000WO-US23328.
10-NOV-2000; 2000WO-US30873.
01-DEC-2000; 2000WO-US32378.
20-DEC-2000; 2000WO-US34956.
28-FEB-2001; 2001WO-US06520.
20-JUN-2001; 2001WO-US19692.
29-JUN-2001; 2001WO-US21086.
09-JUL-2001; 2001WO-US21735.

(GETH) GENENTECH INC.

Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

WPI: 2002-731348/79.
N-PSDB; ABS74390.

New isolated secreted and transmembrane PRO polypeptide useful for modulating biological activity of a cell, or for treating sports-related joint problems, osteoarthritis or rheumatoid arthritis

Claim 20; Fig 26; 399pp; English.

The invention relates to an isolated secreted and transmembrane PRO polypeptide having 80 % sequence identity to a sequence appearing as ABG5851-ABG5934 or their associated signal peptide, or a sequence of an extracellular domain of the proteins with their associated signal peptide or lacking its associated signal peptide. Also included are the nucleic acids encoding the proteins, vectors, host cells, fusion proteins and antibodies which specifically bind to the proteins. The proteins are useful for detecting a polypeptide designated as A, B, C or D in a sample suspected of containing an A, B, C or D polypeptide, by contacting the sample with a polypeptide designated as A, B, C or D (or vice versa) and determining the formation of a A/E, B/F, G/G, C/H or D/I polypeptide conjugate in the sample, where the formation of the conjugate is indicative of the presence of an A, B, C or D polypeptide in the sample, where A is a PRO10272 polypeptide, B is a PRO20110 polypeptide, C is a PRO10096 polypeptide, D is a PRO19760 polypeptide, E is a PRO5801 polypeptide, F is a PRO1 polypeptide, G is a PRO20040 polypeptide, H is a PRO20233 polypeptide and I is a PRO1890 polypeptide. The sample comprises a cell suspected of expressing the A, B, C or D polypeptide. The E, F, G, H or I polypeptide is labeled with a detectable label or is attached to a solid support. The proteins are useful for linking a bioactive molecule to a cell expressing a

polypeptide designated as A, B, C or D or E, F, G, H or I. The bioactive molecule is a toxin, a radiolabel or an antibody. The bioactive molecule causes death of the cell. A, B, C, D, E, F, G, H, or I, or antibodies against them are useful for modulating a biological activity of a cell expressing a polypeptide designated as A, B, C or D or E, F, G, H, or I. The cell is killed. The proteins are useful for identifying agonists or antagonists for the preparation of a medicament useful in the treatment of a condition which is responsive to the proteins, as molecular weight markers for protein electrophoresis purposes, and as therapeutic agents for treating sports-related joint problems, articular cartilage defects, osteoarthritis or rheumatoid arthritis. Nucleic acids encoding the proteins are useful as hybridisation probes, in chromosome and gene mapping, in the generation of anti-sense RNA and DNA, for the preparation of the proteins, to generate transgenic or knockout animals which are useful in the development and screening of therapeutic useful reagents, for chromosome identification, and in gene therapy. The antibody is useful as a therapeutic agent, in a diagnostic assay and for affinity purification of the protein from recombinant cell culture natural sources. The present sequence represents a novel secreted or transmembrane protein of the invention.

Query Match 100.0%; Score 119; DB 23; Length 119;
Best Local Similarity 100.0%; Pred. No. 3.3e-110;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MKVLISSLLILLPLMLMSVSSSLNPGVARGHRDQASRRWLQGGQCECKQWFLRAP 60
DB 1 MKVLISSLLILLPLMLMSVSSSLNPGVARGHRDQASRRWLQGGQCECKQWFLRAP 60
QY 61 RRKFWTVSGLPKQPCDHFKNVKKTRQHRKPKNKHSHRACQFLKQCQLRSFALPL 119
DB 61 RRKFWTVSGLPKQPCDHFKNVKKTRQHRKPKNKHSHRACQFLKQCQLRSFALPL 119

RESULT 11

ABU71181
ID ABU71181 standard; Protein; 119 AA.
XX AC ABU71181;
DT 10-JUN-2003 (first entry)
XX DE Human PRO842 protein.
XX KW Human; PRO; secreted; transmembrane; cytostatic; TNF-alpha; blood; tumour necrosis factor alpha release; chondrocyte cell; proliferation; differentiation; tumour; gene therapy.
XX OS Homo sapiens.
XX PN US2003036143-A1.
XX PD 20-FEB-2003.
XX PF 02-JUL-2002; 2002US-0187600.
XX PR 16-SEP-1998; 98WO-US19330.
XX PR 07-OCT-1998; 98WO-US21141.
XX PR 01-DEC-1998; 98WO-US25108.
XX PR 08-MAR-1999; 99WO-US05028.
XX PR 14-MAY-1999; 99WO-US10733.
XX PR 02-JUN-1999; 99WO-US12252.
XX PR 01-SEP-1999; 99WO-US20111.
XX PR 15-SEP-1999; 99WO-US21090.
XX PR 01-DEC-1999; 99WO-US28301.
XX PR 02-DEC-1999; 99WO-US28551.
XX PR 30-DEC-1999; 99WO-US31274.
XX PR 05-JAN-2000; 2000WO-US00319.
XX PR 18-FEB-2000; 2000WO-US04341.
XX PR 18-FEB-2000; 2000WO-US04342.
XX PR 22-FEB-2000; 2000WO-US04414.

14-FEB-2000;	2000WO-US05004.	PR	15-MAY-1998;	98US-085700P.
11-MAR-2000;	2000WO-US05601.	PR	18-MAY-1998;	98US-086023P.
12-MAR-2000;	2000WO-US05841.	PR	22-MAY-1998;	98US-086392P.
5-MAR-2000;	2000WO-US06884.	PR	22-MAY-1998;	98US-086486P.
10-MAR-2000;	2000WO-US08439.	PR	28-MAY-1998;	98US-087098P.
7-MAY-2000;	2000WO-US13705.	PR	28-MAY-1998;	98US-087208P.
12-MAY-2000;	2000WO-US14042.	PR	02-JUN-1998;	98US-087609P.
10-MAY-2000;	2000WO-US14941.	PR	02-JUN-1998;	98US-087759P.
12-JUN-2000;	2000WO-US15264.	PR	03-JUN-1998;	98US-087827P.
18-JUL-2000;	2000WO-US07710.	PR	04-JUN-1998;	98US-088025P.
4-AUG-2000;	2000WO-US03328.	PR	04-JUN-1998;	98US-088028P.
18-NOV-2000;	2000WO-US03952.	PR	04-JUN-1998;	98US-088029P.
11-DEC-2000;	2000WO-US32678.	PR	04-JUN-1998;	98US-088033P.
10-DEC-2000;	2000WO-US34956.	PR	04-JUN-1998;	98US-088326P.
18-FEB-2001;	2001WO-US06520.	PR	05-JUN-1998;	98US-088167P.
11-JUN-2001;	2001WO-US17800.	PR	05-JUN-1998;	98US-088202P.
30-JUN-2001;	2001WO-US19692.	PR	05-JUN-1998;	98US-088212P.
29-JUN-2001;	2001WO-US21066.	PR	05-JUN-1998;	98US-088217P.
19-JUL-2001;	2001WO-US21735.	PR	09-JUN-1998;	98US-088655P.
29-AUG-2001;	2001WO-US27099.	PR	10-JUN-1998;	98US-088722P.
16-SEP-1997;	97US-059263P.	PR	10-JUN-1998;	98US-088738P.
18-SEP-1997;	97US-059266P.	PR	10-JUN-1998;	98US-088740P.
17-OCT-1997;	97US-062250P.	PR	10-JUN-1998;	98US-088811P.
21-OCT-1997;	97US-063486P.	PR	10-JUN-1998;	98US-088824P.
24-OCT-1997;	97US-063120P.	PR	10-JUN-1998;	98US-088825P.
28-OCT-1997;	97US-063122P.	PR	10-JUN-1998;	98US-088826P.
28-OCT-1997;	97US-063540P.	PR	10-JUN-1998;	98US-088861P.
28-OCT-1997;	97US-063544P.	PR	11-JUN-1998;	98US-088863P.
28-OCT-1997;	97US-063566P.	PR	11-JUN-1998;	98US-088876P.
29-OCT-1997;	97US-063734P.	PR	12-JUN-1998;	98US-089090P.
31-OCT-1997;	97US-063870P.	PR	12-JUN-1998;	98US-089105P.
31-OCT-1997;	97US-064103P.	PR	15-JUN-1998;	98US-089512P.
13-NOV-1997;	97US-065311P.	PR	15-JUN-1998;	98US-089514P.
21-NOV-1997;	97US-066120P.	PR	17-JUN-1998;	98US-089538P.
24-NOV-1997;	97US-066466P.	PR	17-JUN-1998;	98US-089598P.
24-NOV-1997;	97US-066772P.	PR	17-JUN-1998;	98US-089653P.
11-DEC-1997;	97US-069335P.	PR	18-JUN-1998;	98US-089908P.
12-DEC-1997;	97US-069425P.	PR	19-JUN-1998;	98US-089952P.
17-DEC-1997;	97US-069870P.	PR	22-JUN-1998;	98US-090246P.
18-DEC-1997;	97US-068017P.	PR	22-JUN-1998;	98US-090252P.
10-MAR-1998;	98US-072450P.	PR	22-JUN-1998;	98US-090254P.
11-MAR-1998;	98US-077632P.	PR	24-JUN-1998;	98US-090429P.
11-MAR-1998;	98US-077649P.	PR	24-JUN-1998;	98US-090435P.
20-MAR-1998;	98US-078886P.	PR	24-JUN-1998;	98US-090444P.
20-MAR-1998;	98US-078939P.	PR	24-JUN-1998;	98US-090461P.
27-MAR-1998;	98US-079664P.	PR	24-JUN-1998;	98US-090535P.
31-MAR-1998;	98US-079786P.	PR	24-JUN-1998;	98US-090540P.
31-MAR-1998;	98US-080107P.	PR	25-JUN-1998;	98US-090676P.
01-APR-1998;	98US-080194P.	PR	25-JUN-1998;	98US-090678P.
01-APR-1998;	98US-080327P.	PR	25-JUN-1998;	98US-090688P.
01-APR-1998;	98US-080333P.	PR	25-JUN-1998;	98US-090690P.
08-APR-1998;	98US-081049P.	PR	25-JUN-1998;	98US-090694P.
08-APR-1998;	98US-081070P.	PR	25-JUN-1998;	98US-090695P.
09-APR-1998;	98US-081195P.	PR	25-JUN-1998;	98US-090696P.
15-APR-1998;	98US-081838P.	PR	26-JUN-1998;	98US-090862P.
21-APR-1998;	98US-082568P.	PR	26-JUN-1998;	98US-090863P.
21-APR-1998;	98US-083569P.	PR	26-JUN-1998;	98US-090863P.
22-APR-1998;	98US-082704P.	PR	01-JUL-1998;	98US-091359P.
22-APR-1998;	98US-082757P.	PR	01-JUL-1998;	98US-091544P.
28-APR-1998;	98US-083322P.	PR	02-JUL-1998;	98US-091478P.
29-APR-1998;	98US-083495P.	PR	02-JUL-1998;	98US-091486P.
29-APR-1998;	98US-083496P.	PR	02-JUL-1998;	98US-091626P.
29-APR-1998;	98US-083499P.	PR	02-JUL-1998;	98US-091628P.
29-APR-1998;	98US-083559P.	PR	02-JUL-1998;	98US-091632P.
05-MAY-1998;	98US-084366P.	PR	24-JUL-1998;	98US-094006P.
06-MAY-1998;	98US-084414P.	PR	04-AUG-1998;	98US-095282P.
07-MAY-1998;	98US-084639P.	PR	10-AUG-1998;	98US-095998P.
07-MAY-1998;	98US-084640P.	PR	10-AUG-1998;	98US-096012P.
07-MAY-1998;	98US-084643P.	PR	17-AUG-1998;	98US-096757P.
15-MAY-1998;	98US-085579P.	PR	17-AUG-1998;	98US-096766P.
15-MAY-1998;	98US-085580P.	PR	17-AUG-1998;	98US-096891P.
15-MAY-1998;	98US-085582P.	PR	17-AUG-1998;	98US-096897P.

18-AUG-1998; 98US-096949P.
 18-AUG-1998; 98US-096959P.
 18-AUG-1998; 98US-097022P.
 26-AUG-1998; 98US-097952P.
 26-AUG-1998; 98US-097954P.
 26-AUG-1998; 98US-097955P.
 26-AUG-1998; 98US-097971P.
 26-AUG-1998; 98US-097974P.
 26-AUG-1998; 98US-098014P.
 01-SEP-1998; 98US-098716P.
 01-SEP-1998; 98US-098723P.
 02-SEP-1998; 98US-098803P.
 02-SEP-1998; 98US-098821P.
 02-SEP-1998; 98US-098843P.
 09-SEP-1998; 98US-099602P.
 10-SEP-1998; 98US-099741P.
 10-SEP-1998; 98US-099754P.
 10-SEP-1998; 98US-099763P.
 10-SEP-1998; 98US-099812P.

Query Match 100.0%; Score 119; DB 24; Length 119;
 Local Similarity 100.0%; Pred. No. 3.3e-110;
 Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDQASRWLQEGGQCECKDWFRLAP 60
 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDQASRWLQEGGQCECKDWFRLAP 60
 61 RRKFTVSGLPKQPCDHFKNVKTTHORHRRKPNKHSRACQFLKQQLRSFALPL 119
 61 RRKFTVSGLPKQPCDHFKNVKTTHORHRRKPNKHSRACQFLKQQLRSFALPL 119

JT 12

L518

ABU71518 standard; Protein; 119 AA.

ABU71518;

10-JUN-2003 (first entry)

Human secreted polypeptide PRO842.

Human; gene therapy; tumour; cancer.

Homo sapiens.

US2003013855-A1.

16-JAN-2003.

03-MAY-2002; 2002US-0063616.

30-DEC-1998; 98KR-0062142.
 08-MAR-1999; 99WO-US05028.
 14-MAY-1999; 99WO-US10733.
 30-DEC-1999; 99WO-US31274.
 18-FEB-2000; 2000WO-US04341.
 01-MAR-2000; 2000WO-US05601.
 02-MAR-2000; 2000WO-US05841.
 21-MAR-2000; 2000WO-US07532.
 22-MAY-2000; 2000WO-US14042.
 02-JUN-2000; 2000WO-US15264.
 24-AUG-2000; 2000WO-US23328.
 10-NOV-2000; 2000WO-US30873.
 01-DEC-2000; 2000WO-US32678.
 20-DEC-2000; 2000WO-US34956.
 28-FEB-2001; 2001WO-US06520.
 01-JUN-2001; 2001WO-US17800.
 14-MAY-1999; 99US-0311832.
 25-AUG-1999; 99US-0380137.
 25-AUG-1999; 99US-0380138.
 25-AUG-1999; 99US-0380139.

25-AUG-1999; 99US-0380142.
 15-SEP-1999; 99US-0397342.
 18-OCT-1999; 99US-0403297.
 12-NOV-1999; 99US-0423844.
 22-AUG-2000; 2000US-0644848.
 18-SEP-2000; 2000US-0664610.
 18-SEP-2000; 2000US-0664610.
 08-NOV-2000; 2000US-0709238.
 20-DEC-2000; 2000US-0747259.
 22-MAR-2001; 2001US-0816744.
 10-MAY-2001; 2001US-0854208.
 10-MAY-2001; 2001US-0854280.
 30-MAY-2001; 2001US-0870574.
 05-JUN-2001; 2001US-0874503.
 29-JUN-2001; 2001US-0869599.
 18-JUL-2001; 2001US-0908827.
 06-DEC-2001; 2001US-0006867.
 (GETH) GENENTECH INC.

Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski FJ;
 Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;

WPI; 2003-330485/31.

N-PSDB; ACA58922.

New isolated antibody specifically binding a PRO polypeptide, useful
 for the preparation of a medicament for treating disorders with the
 aberrant expression or activity of the PRO polypeptide, such as tumor
 conditions and cancer -

Disclosure; Page 93; 406pp; English.

The invention relates to an antibody that binds to a polypeptide with a
 fully defined sequence given in the specification. The methods and
 compositions (containing antibodies that specifically bind a PRO
 polypeptide) of the present invention are useful for the preparation of a
 medicament for the treatment of disorders associated with the aberrant
 expression or activity of the PRO polypeptide, such as tumour conditions
 and cancer. They can also be used to generate transgenic or knockout
 animals useful in the development and screening of therapeutically useful
 reagents. The PRO polypeptides and encoding nucleic acids can be used as
 molecular weight markers for protein electrophoresis, chromosome
 identification and tissue typing. The PRO polypeptides are useful to
 induce angiogenesis e.g wound healing; in the treatment of sports-related
 joint problems, articular cartilage defects, osteoarthritis or rheumatoid
 arthritis; diabetes; hyperinsulinaemia and hypoinsulinaemia. The
 antibodies may be used in various diagnostic, competitive binding and/or
 immunoprecipitation assays. The present sequence represents the amino
 acid sequence of a PRO polypeptide of the invention.

SQ Sequence 119 AA;

Query Match 100.0%; Score 119; DB 24; Length 119;
 Best Local Similarity 100.0%; Pred. No. 3.3e-110;
 Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDQASRWLQEGGQCECKDWFRLAP 60

Db 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDQASRWLQEGGQCECKDWFRLAP 60

QY 61 RRKFTVSGLPKQPCDHFKNVKTTHORHRRKPNKHSRACQFLKQQLRSFALPL 119

Db 61 RRKFTVSGLPKQPCDHFKNVKTTHORHRRKPNKHSRACQFLKQQLRSFALPL 119

RESULT 13

ABU71964

ID ABU71964 standard; Protein; 119 AA.

XX ABU71964;

DT 11-JUN-2003 (first entry)

ovel human secreted and transmembrane protein PRO842.
uman; secreted and transmembrane polypeptide;
hromosome mapping; gene mapping; transgenic animal; knockout animal;
herapeutic agent screening; chromosome identification; tissue typing;
ene therapy.
omo sapiens.
S2003018183-A1.
3-JAN-2003.
1-MAY-2002; 2002US-0063512.
6-DEC-2001; 2001US-0006967.
GETH) GENENTECH INC.
aton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
rimaldi JC, Gurney AL, Watanabe CK, Wood WI;
PI; 2003-330984/31.
I-PSDB; ACA60375.
lew secreted and transmembrane PRO polypeptides and nucleic acid
olecules encoding the polypeptides, useful in gene therapy or
reparing a medicament for treating a condition that is responsive to
he PRO polypeptide or antibody -
isclosure; Fig 26; 409pp; English.
he invention describes novel isolated PRO polypeptides. The PRO
polypeptides or anti-PRO antibodies are useful in preparing a medicament
or treating a condition that is responsive to the PRO polypeptide or
ntibody. The PRO nucleotide sequences may be used as hybridisation
robes in chromosome and gene mapping, or in generating antisense RNA
nd DNA. PRO nucleic acids are also useful in preparing PRO polypeptides,
n assays to identify other proteins or molecules involved in binding
reaction, to generate transgenic animals or knockout animals, which in
urn are useful in the development and screening of therapeutically
seful reagents, for chromosome identification, and tissue typing. The
PRO polypeptides and nucleic acid molecules are also useful in gene
herapy, and as molecular weight markers for protein electrophoresis
urposes. The anti-PRO antibodies may be used in diagnostic assays for
PRO, or for the affinity purification of PRO from recombinant cell
ulture or natural sources. This is the amino acid sequence of a novel
uman secreted and transmembrane PRO polypeptide.
Sequence 119 AA;
ry Match 100.0%; Score 119; DB 24; Length 119;
Local Similarity 100.0%; Pred. No. 3.3e-110;
ches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDGRQASRWLQEGGQCECKDWFLRAP 60
1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDGRQASRWLQEGGQCECKDWFLRAP 60
61 RRKFMTVSGLPKQCPDHFPGNVKTRHORHHRKPNKHSRACQQLKQQLRSFALPL 119
61 RRKFMTVSGLPKQCPDHFPGNVKTRHORHHRKPNKHSRACQQLKQQLRSFALPL 119
T 14
121
ABU72121;
13-JUN-2003 (first entry)
Human secreted/transmembrane protein, SEQ ID 140.
Human; PRO; secreted protein; transmembrane protein;
cytostatic; antiarthritic; osteopathic; adrenal tumour; lung tumour;
colon tumour; breast tumour; prostate tumour; rectal tumour;
cervical tumour; liver tumour; TNF-alpha release; arthritis;
tumour necrosis factor alpha; chondrocyte cell; bone disorder;
cartilage disorder; sports injury.
Homo sapiens.

Human PRO polypeptide #13.
Human; PRO polypeptide; secreted and transmembrane protein;
anti-PRO antibody; diagnostic assay; gene expression.
Homo sapiens.
US2003023042-A1.
30-JAN-2003.
01-MAY-2002; 2002US-0063502.
06-DEC-2001; 2001US-0006967.
(GETH) GENENTECH INC.
Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;
Grimaldi JC, Gurney AL, Watanabe CK, Wood WI;
N-PSDB; ACA63385.
WPI; 2003-331484/31.
Novel monoclonal antibody that binds to secreted and transmembrane
polypeptide useful for detecting and purifying the polypeptide and
also for treating conditions responsive to the antibody -
Disclosure; Fig 26; 408pp; English.
The present invention relates to the isolation of novel human PRO
polypeptides, and the polynucleotide sequences encoding them. The
PRO polypeptides are secreted and transmembrane proteins. The PRO
polypeptides and polynucleotides are useful for preparing a
medicament useful in the treatment of a condition responsive to
anti-PRO antibody. Anti-PRO antibodies are useful in diagnostic
assays for PRO, by detecting its expression in specific cells,
tissues or serum, and for affinity purification of PRO from
recombinant cell culture or natural sources. ABU72109-ABU72192
represent the human PRO polypeptides of the invention.
Sequence 119 AA;
Query Match 100.0%; Score 119; DB 24; Length 119;
Best Local Similarity 100.0%; Pred. No. 3.3e-110;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDGRQASRWLQEGGQCECKDWFLRAP 60
DB 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDGRQASRWLQEGGQCECKDWFLRAP 60
QY 61 RRKFMTVSGLPKQCPDHFPGNVKTRHORHHRKPNKHSRACQQLKQQLRSFALPL 119
DB 61 RRKFMTVSGLPKQCPDHFPGNVKTRHORHHRKPNKHSRACQQLKQQLRSFALPL 119
RESULT 15
ABU65638
ID ABU65638 standard; Protein; 119 AA.
AC ABU65638;
XX 19-MAY-2003 (first entry)
DT Human secreted/transmembrane protein, SEQ ID 140.
DE
XX
KW Human; PRO; secreted protein; transmembrane protein;
cytostatic; antiarthritic; osteopathic; adrenal tumour; lung tumour;
colon tumour; breast tumour; prostate tumour; rectal tumour;
cervical tumour; liver tumour; TNF-alpha release; arthritis;
tumour necrosis factor alpha; chondrocyte cell; bone disorder;
cartilage disorder; sports injury.
Homo sapiens.

US2003036156-A1.
20-FEB-2003.
02-JUL-2002; 2002US-0188767.
16-SEP-1998; 98WO-US19330.
07-OCT-1998; 98WO-US21141.
01-DEC-1998; 98WO-US25108.
08-MAR-1999; 99WO-US05028.
14-MAY-1999; 99WO-US10733.
02-JUN-1999; 99WO-US12252.
01-SEP-1999; 99WO-US20111.
15-SEP-1999; 99WO-US20100.
01-DEC-1999; 99WO-US28301.
02-DEC-1999; 99WO-US28551.
30-DEC-1999; 99WO-US31274.
05-JAN-2000; 2000WO-US00219.
18-FEB-2000; 2000WO-US04341.
18-FEB-2000; 2000WO-US04342.
22-FEB-2000; 2000WO-US04414.
24-FEB-2000; 2000WO-US05004.
01-MAR-2000; 2000WO-US05601.
02-MAR-2000; 2000WO-US05841.
15-MAR-2000; 2000WO-US06884.
30-MAR-2000; 2000WO-US08439.
17-MAY-2000; 2000WO-US13705.
22-MAY-2000; 2000WO-US14042.
30-MAY-2000; 2000WO-US14941.
02-JUN-2000; 2000WO-US15264.
28-JUL-2000; 2000WO-US20710.
24-AUG-2000; 2000WO-US23328.
08-NOV-2000; 2000WO-US30952.
01-DEC-2000; 2000WO-US32678.
20-DEC-2000; 2000WO-US34956.
28-FEB-2001; 2001WO-US06520.
01-JUN-2001; 2001WO-US17800.
20-JUN-2001; 2001WO-US19692.
29-JUN-2001; 2001WO-US21066.
09-JUL-2001; 2001WO-US21735.
29-AUG-2001; 2001WO-US27099.
18-SEP-1997; 97US-US09263P.
18-SEP-1997; 97US-US09266P.
17-OCT-1997; 97US-US02250P.
21-OCT-1997; 97US-US03486P.
24-OCT-1997; 97US-US03120P.
24-OCT-1997; 97US-US03121P.
28-OCT-1997; 97US-US03540P.
28-OCT-1997; 97US-US03541P.
28-OCT-1997; 97US-US03544P.
29-OCT-1997; 97US-US03564P.
29-OCT-1997; 97US-US03734P.
31-OCT-1997; 97US-US03870P.
31-OCT-1997; 97US-US04103P.
13-NOV-1997; 97US-US05311P.
21-NOV-1997; 97US-US06120P.
24-NOV-1997; 97US-US06466P.
24-NOV-1997; 97US-US06772P.
11-DEC-1997; 97US-US09335P.
12-DEC-1997; 97US-US09425P.
17-DEC-1997; 97US-US09870P.
18-DEC-1997; 97US-US08017P.
10-MAR-1998; 98US-US077450P.
11-MAR-1998; 98US-US077632P.
11-MAR-1998; 98US-US077649P.
20-MAR-1998; 98US-US078886P.
20-MAR-1998; 98US-US078939P.
27-MAR-1998; 98US-US079664P.
27-MAR-1998; 98US-US079786P.
31-MAR-1998; 98US-US080107P.
31-MAR-1998; 98US-US080194P.
01-APR-1998; 98US-US080327P.
01-APR-1998; 98US-US080333P.
08-APR-1998; 98US-US081049P.
08-APR-1998; 98US-US081070P.
09-APR-1998; 98US-US081195P.
15-APR-1998; 98US-US081838P.
21-APR-1998; 98US-US082568P.
21-APR-1998; 98US-US082569P.
22-APR-1998; 98US-US082704P.
22-APR-1998; 98US-US082797P.
28-APR-1998; 98US-US083222P.
29-APR-1998; 98US-US083445P.
29-APR-1998; 98US-US083456P.
29-APR-1998; 98US-US083499P.
29-APR-1998; 98US-US083559P.
05-MAY-1998; 98US-US084366P.
06-MAY-1998; 98US-US084414P.
07-MAY-1998; 98US-US084639P.
07-MAY-1998; 98US-US084640P.
15-MAY-1998; 98US-US084643P.
15-MAY-1998; 98US-US085579P.
15-MAY-1998; 98US-US085580P.
15-MAY-1998; 98US-US085582P.
15-MAY-1998; 98US-US085700P.
18-MAY-1998; 98US-US086023P.
22-MAY-1998; 98US-US086392P.
22-MAY-1998; 98US-US086486P.
28-MAY-1998; 98US-US087098P.
28-MAY-1998; 98US-US087208P.
02-JUN-1998; 98US-US087609P.
02-JUN-1998; 98US-US087759P.
03-JUN-1998; 98US-US088025P.
04-JUN-1998; 98US-US088028P.
04-JUN-1998; 98US-US088029P.
04-JUN-1998; 98US-US088033P.
04-JUN-1998; 98US-US088326P.
05-JUN-1998; 98US-US088167P.
05-JUN-1998; 98US-US088202P.
05-JUN-1998; 98US-US088212P.
05-JUN-1998; 98US-US088217P.
09-JUN-1998; 98US-US088655P.
10-JUN-1998; 98US-US088722P.
10-JUN-1998; 98US-US088738P.
10-JUN-1998; 98US-US088740P.
10-JUN-1998; 98US-US088811P.
10-JUN-1998; 98US-US088824P.
10-JUN-1998; 98US-US088825P.
10-JUN-1998; 98US-US088826P.
11-JUN-1998; 98US-US088861P.
11-JUN-1998; 98US-US088863P.
11-JUN-1998; 98US-US088876P.
12-JUN-1998; 98US-US089090P.
12-JUN-1998; 98US-US09105P.
16-JUN-1998; 98US-US09512P.
16-JUN-1998; 98US-US09514P.
17-JUN-1998; 98US-US09538P.
17-JUN-1998; 98US-US09539P.
17-JUN-1998; 98US-US09553P.
18-JUN-1998; 98US-US09908P.
19-JUN-1998; 98US-US09952P.
22-JUN-1998; 98US-US09246P.
22-JUN-1998; 98US-US09252P.
22-JUN-1998; 98US-US09254P.
24-JUN-1998; 98US-US09429P.
24-JUN-1998; 98US-US09435P.
24-JUN-1998; 98US-US09444P.
24-JUN-1998; 98US-US09461P.
24-JUN-1998; 98US-US09535P.
24-JUN-1998; 98US-US09540P.
25-JUN-1998; 98US-US09676P.
25-JUN-1998; 98US-US09678P.
25-JUN-1998; 98US-US09688P.
25-JUN-1998; 98US-US09690P.

[illegible]

```

21-APR-1998; 98US-082568P.
22-APR-1998; 98US-082569P.
22-APR-1998; 98US-082704P.
22-APR-1998; 98US-082797P.
28-APR-1998; 98US-083332P.
29-APR-1998; 98US-083495P.
29-APR-1998; 98US-083496P.
29-APR-1998; 98US-083499P.
29-APR-1998; 98US-083592P.
05-MAY-1998; 98US-083566P.
06-MAY-1998; 98US-084414P.
07-MAY-1998; 98US-084639P.
07-MAY-1998; 98US-084640P.
07-MAY-1998; 98US-084643P.
15-MAY-1998; 98US-085579P.
15-MAY-1998; 98US-085580P.
15-MAY-1998; 98US-085582P.
15-MAY-1998; 98US-085700P.
18-MAY-1998; 98US-086023P.
22-MAY-1998; 98US-086392P.
22-MAY-1998; 98US-086486P.
28-MAY-1998; 98US-087098P.
28-MAY-1998; 98US-087208P.
02-JUN-1998; 98US-087609P.
02-JUN-1998; 98US-087758P.
03-JUN-1998; 98US-087827P.
04-JUN-1998; 98US-088025P.
04-JUN-1998; 98US-088028P.
04-JUN-1998; 98US-088029P.
04-JUN-1998; 98US-088033P.
04-JUN-1998; 98US-088326P.
05-JUN-1998; 98US-088167P.
05-JUN-1998; 98US-088202P.
05-JUN-1998; 98US-088212P.
05-JUN-1998; 98US-088217P.
09-JUN-1998; 98US-088655P.
10-JUN-1998; 98US-088722P.
10-JUN-1998; 98US-088738P.
10-JUN-1998; 98US-088740P.
10-JUN-1998; 98US-088811P.
10-JUN-1998; 98US-088824P.
10-JUN-1998; 98US-088835P.
10-JUN-1998; 98US-088861P.
11-JUN-1998; 98US-088863P.
11-JUN-1998; 98US-088876P.
12-JUN-1998; 98US-089090P.
12-JUN-1998; 98US-089105P.
16-JUN-1998; 98US-089512P.
16-JUN-1998; 98US-089514P.
17-JUN-1998; 98US-089558P.
17-JUN-1998; 98US-089598P.
17-JUN-1998; 98US-089653P.
18-JUN-1998; 98US-089908P.
19-JUN-1998; 98US-089952P.
22-JUN-1998; 98US-090246P.
22-JUN-1998; 98US-090252P.
22-JUN-1998; 98US-090254P.
24-JUN-1998; 98US-090439P.
24-JUN-1998; 98US-090435P.
24-JUN-1998; 98US-090444P.
24-JUN-1998; 98US-090461P.
24-JUN-1998; 98US-090535P.
24-JUN-1998; 98US-090540P.
25-JUN-1998; 98US-090676P.
25-JUN-1998; 98US-090678P.
25-JUN-1998; 98US-090688P.
25-JUN-1998; 98US-090690P.
25-JUN-1998; 98US-090694P.
25-JUN-1998; 98US-090695P.
25-JUN-1998; 98US-090696P.
26-JUN-1998; 98US-090862P.
26-JUN-1998; 98US-090863P.

26-JUN-1998; 98US-091010P.
01-JUL-1998; 98US-091359P.
01-JUL-1998; 98US-091544P.
02-JUL-1998; 98US-091478P.
02-JUL-1998; 98US-091486P.
02-JUL-1998; 98US-091626P.
02-JUL-1998; 98US-091628P.
02-JUL-1998; 98US-091632P.
24-JUL-1998; 98US-094006P.
04-AUG-1998; 98US-095282P.
10-AUG-1998; 98US-095998P.
10-AUG-1998; 98US-096012P.
17-AUG-1998; 98US-096757P.
17-AUG-1998; 98US-096766P.
17-AUG-1998; 98US-096867P.
17-AUG-1998; 98US-096891P.
17-AUG-1998; 98US-096897P.
18-AUG-1998; 98US-096949P.
18-AUG-1998; 98US-096959P.
18-AUG-1998; 98US-097022P.
26-AUG-1998; 98US-097952P.
26-AUG-1998; 98US-097954P.
26-AUG-1998; 98US-097955P.
26-AUG-1998; 98US-097971P.
26-AUG-1998; 98US-097974P.
26-AUG-1998; 98US-098014P.
01-SEP-1998; 98US-098716P.
01-SEP-1998; 98US-098723P.
02-SEP-1998; 98US-098803P.
02-SEP-1998; 98US-098821P.
02-SEP-1998; 98US-098843P.
09-SEP-1998; 98US-098602P.
10-SEP-1998; 98US-098741P.
10-SEP-1998; 98US-098754P.
10-SEP-1998; 98US-098763P.

Query Match 100.0%; Score 119; DB 24; Length 119;
Best Local Similarity 100.0%; Pred. No. 3.3e-110;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MKVLISLLLLPLMLSMVSSSLNPGVARGHRRGQASRRWLQEGGQCECKDWFRLAP 60
Db 1 MKVLISLLLLPLMLSMVSSSLNPGVARGHRRGQASRRWLQEGGQCECKDWFRLAP 60
QY 61 RRKEMTVSGLPKQCPDHFKNVKKTRHRRHKKPKHRSRACQFLKQCQLRSFALPL 119
Db 61 RRKEMTVSGLPKQCPDHFKNVKKTRHRRHKKPKHRSRACQFLKQCQLRSFALPL 119

RESULT 17
ABU67475
ID ABU67475 standard; Protein; 119 AA.
XX
AC ABU67475;
XX
DT 29-MAY-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) #70.
XX
KW Human; secreted and transmembrane protein; PRO; TNF-alpha;
tumor necrosis factor alpha; chondrocyte cell; tumour; gene therapy;
tissue typing.
XX
OS Homo sapiens.
XX
US2003036162-A1.
PD 20-FEB-2003.
XX
PF 12-JUL-2002; 2002US-0194423.
XX
PR 16-SEP-1998; 98WO-US19330.
PR 07-OCT-1998; 98WO-US21141.

```

11-DEC-1998; 98WO-US25108.
 18-MAR-1999; 99WO-US05028.
 4-MAY-1999; 99WO-US10733.
 12-JUN-1999; 99WO-US12252.
 1-SEP-1999; 99WO-US20111.
 5-SEP-1999; 99WO-US21090.
 11-DEC-1999; 99WO-US28301.
 12-DEC-1999; 99WO-US28551.
 10-DEC-1999; 99WO-US31274.
 15-JAN-2000; 2000WO-US00219.
 8-FEB-2000; 2000WO-US04341.
 8-FEB-2000; 2000WO-US04342.
 2-FEB-2000; 2000WO-US04414.
 4-FEB-2000; 2000WO-US05004.
 11-MAR-2000; 2000WO-US05601.
 12-MAR-2000; 2000WO-US05841.
 5-MAR-2000; 2000WO-US06884.
 10-MAR-2000; 2000WO-US08439.
 17-MAY-2000; 2000WO-US13705.
 22-MAY-2000; 2000WO-US14042.
 10-MAY-2000; 2000WO-US14941.
 22-JUN-2000; 2000WO-US15264.
 28-JUL-2000; 2000WO-US20710.
 14-AUG-2000; 2000WO-US23328.
 18-NOV-2000; 2000WO-US30952.
 31-NOV-2000; 2000WO-US32678.
 20-DEC-2000; 2000WO-US34956.
 28-FEB-2001; 2001WO-US06520.
 31-JUN-2001; 2001WO-US17800.
 20-JUN-2001; 2001WO-US19692.
 29-JUN-2001; 2001WO-US21066.
 19-JUL-2001; 2001WO-US21735.
 29-AUG-2001; 2001WO-US27099.
 26-JUN-1998; 98US-0105413.
 37-OCT-1998; 98US-0168978.
 36-NOV-1998; 98US-0187368.
 07-DEC-1998; 98US-0202054.
 03-MAR-1999; 99US-0254311.
 14-MAY-1999; 99US-0311832.
 25-AUG-1999; 99US-0380137.
 25-AUG-1999; 99US-0380138.
 25-AUG-1999; 99US-0380139.
 23-AUG-1999; 99US-0380142.
 18-OCT-1999; 99US-0403297.
 12-NOV-1999; 99US-0423844.
 22-AUG-2000; 2000US-0644848.
 18-SEP-2000; 2000US-0664610.
 18-SEP-2000; 2000US-0665350.
 08-NOV-2000; 2000US-0709238.
 20-DEC-2000; 2000US-0747259.
 22-MAR-2001; 2001US-0816744.
 10-MAY-2001; 2001US-0854208.
 10-MAY-2001; 2001US-0854280.
 25-MAY-2001; 2001US-0866028.
 05-JUN-2001; 2001US-0874503.
 18-JUL-2001; 2001US-0908827.
 30-JUL-2001; 2001US-0918585.
 06-AUG-2001; 2001US-0924419.
 13-AUG-2001; 2001US-0929404.
 16-AUG-2001; 2001US-0931836.
 28-AUG-2001; 2001US-0941992.
 04-SEP-2001; 2001US-0946374.
 15-JAN-2002; 2002US-0052886.

(GETH) GENENTECH INC.

Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
 Pan J, Smith V, Watarabe CX, Wood WI, Zhang Z;

WPI; 2003-332039/31.
 N-PSDB; ACA05769.

New secreted and transmembrane PRO polypeptides and nucleic acids,

PT useful in gene therapy, in chromosome and gene mapping, as chromosome
 PT markers, in tissue typing, and in chromosome identification -
 XX Claim 11; Fig 140; 706pp; English.
 XX The invention discloses human nucleic acids encoding secreted and
 CC transmembrane (PRO) polypeptides. Also disclosed is an antibody that
 CC specifically binds to the PRO polypeptide, a method for stimulating the
 CC release of tumour necrosis factor alpha (TNF-alpha) from human blood by
 CC contacting the blood with a PRO polypeptide, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells by contacting the
 CC cells with a PRO polypeptide, a method for detecting the presence of a
 CC tumour in a mammal and an oligonucleotide probe derived from any of the
 CC PRO nucleotide sequences. The nucleotide sequences are useful as probes,
 CC in chromosome and gene mapping, in generating antisense RNA and DNA, in
 CC preparing PRO polypeptides by recombinant techniques and in gene therapy
 CC (e.g. for replacement of defective gene). The PRO polypeptides are useful
 CC as molecular weight markers for protein electrophoresis purposes, for
 CC chromosome identification, as chromosome markers, as therapeutic agents,
 CC for stimulating the release of TNF-alpha from human blood, for
 CC stimulating the proliferation or differentiation of chondrocytes and
 CC detecting the presence of a tumour. The PRO polypeptides and nucleic
 CC acids may also be used diagnostically for tissue typing. The sequences
 CC presented in ABU67406-ABU67710 are the PRO polypeptides of the invention.
 XX SQ Sequence 119 AA;
 Query Match 100.0%; Score 119; DB 24; Length 119;
 Best Local Similarity 100.0%; Pred. No. 3.3e-110;
 Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MKVLISLLILLPLMLSMVSSSLNPGVARGHSDRGQASRWLQEGQCECKDWFLRAP 60
 DB 1 MKVLISLLILLPLMLSMVSSSLNPGVARGHSDRGQASRWLQEGQCECKDWFLRAP 60
 QY 61 RRKFTVSGLPKQPCDHFKNVKTTHQRRHKNPKHGRACQQLKQQLRSFALPL 119
 DB 61 RRKFTVSGLPKQPCDHFKNVKTTHQRRHKNPKHGRACQQLKQQLRSFALPL 119
 RESULT 18
 ABU65333
 ID ABU65333 standard; Protein; 119 AA.
 XX AC ABU65333;
 XX DT 16-MAY-2003 (first entry)
 XX DE Human PRO polypeptide #70.
 XX KW Human; PRO; cytostatic; chromosome mapping; gene mapping;
 KW protein electrophoresis; tumour necrosis factor-alpha; TNF-alpha; blood;
 KW chondrocyte differentiation; chondrocyte proliferation; tumour.
 XX OS Homo sapiens.
 XX PN US2003032102-A1.
 XX PD 13-FEB-2003.
 XX PF 17-JUN-2002; 2002US-0173697.
 XX PR 16-SEP-1998; 98WO-US19330.
 PR 07-OCT-1998; 98WO-US21141.
 PR 01-DEC-1998; 98WO-US25108.
 PR 08-MAR-1999; 99WO-US05028.
 PR 14-MAY-1999; 99WO-US10733.
 PR 02-JUN-1999; 99WO-US12252.
 PR 01-SEP-1999; 99WO-US20111.
 PR 15-SEP-1999; 99WO-US21090.
 PR 01-DEC-1999; 99WO-US28301.
 PR 02-DEC-1999; 99WO-US28551.
 PR 30-DEC-1999; 99WO-US31274.

05-JAN-2000; 2000WO-US00219.
18-FEB-2000; 2000WO-US04341.
18-FEB-2000; 2000WO-US04342.
22-FEB-2000; 2000WO-US04414.
24-FEB-2000; 2000WO-US05004.
01-MAR-2000; 2000WO-US05601.
02-MAR-2000; 2000WO-US05841.
15-MAR-2000; 2000WO-US06884.
30-MAR-2000; 2000WO-US08439.
17-MAY-2000; 2000WO-US13705.
22-MAY-2000; 2000WO-US14042.
30-MAY-2000; 2000WO-US14941.
02-JUN-2000; 2000WO-US15264.
28-JUL-2000; 2000WO-US20710.
24-AUG-2000; 2000WO-US23328.
08-NOV-2000; 2000WO-US30952.
01-DEC-2000; 2000WO-US32678.
20-DEC-2000; 2000WO-US34956.
28-FEB-2001; 2001WO-US06520.
01-JUN-2001; 2001WO-US17800.
20-JUN-2001; 2001WO-US19692.
29-JUN-2001; 2001WO-US21066.
09-JUL-2001; 2001WO-US21735.
23-AUG-2001; 2001WO-US27098.
18-SEP-1997; 97US-059263P.
18-SEP-1997; 97US-059266P.
17-OCT-1997; 97US-062250P.
21-OCT-1997; 97US-063486P.
24-OCT-1997; 97US-063120P.
24-OCT-1997; 97US-063121P.
28-OCT-1997; 97US-063540P.
28-OCT-1997; 97US-063541P.
28-OCT-1997; 97US-063544P.
28-OCT-1997; 97US-063564P.
29-OCT-1997; 97US-063734P.
31-OCT-1997; 97US-064103P.
31-OCT-1997; 97US-065311P.
13-NOV-1997; 97US-065311P.
21-NOV-1997; 97US-066120P.
24-NOV-1997; 97US-066466P.
24-NOV-1997; 97US-066772P.
11-DEC-1997; 97US-069335P.
12-DEC-1997; 97US-069425P.
17-DEC-1997; 97US-069870P.
18-DEC-1997; 97US-068017P.
10-MAR-1998; 98US-077450P.
11-MAR-1998; 98US-077632P.
11-MAR-1998; 98US-077649P.
20-MAR-1998; 98US-078886P.
20-MAR-1998; 98US-078939P.
27-MAR-1998; 98US-079664P.
27-MAR-1998; 98US-079786P.
31-MAR-1998; 98US-080107P.
31-MAR-1998; 98US-080134P.
01-APR-1998; 98US-080327P.
01-APR-1998; 98US-080333P.
08-APR-1998; 98US-081049P.
08-APR-1998; 98US-081070P.
09-APR-1998; 98US-081195P.
15-APR-1998; 98US-081838P.
21-APR-1998; 98US-082568P.
21-APR-1998; 98US-082569P.
22-APR-1998; 98US-082704P.
22-APR-1998; 98US-082797P.
28-APR-1998; 98US-083322P.
29-APR-1998; 98US-083495P.
29-APR-1998; 98US-083496P.
29-APR-1998; 98US-083498P.
29-APR-1998; 98US-083559P.
05-MAY-1998; 98US-084366P.
06-MAY-1998; 98US-084414P.
07-MAY-1998; 98US-084639P.
07-MAY-1998; 98US-084640P.
07-MAY-1998; 98US-084643P.
07-MAY-1998; 98US-085579P.
15-MAY-1998; 98US-085580P.
15-MAY-1998; 98US-085582P.
15-MAY-1998; 98US-085700P.
18-MAY-1998; 98US-086023P.
22-MAY-1998; 98US-086392P.
22-MAY-1998; 98US-086486P.
28-MAY-1998; 98US-087098P.
28-MAY-1998; 98US-087208P.
02-JUN-1998; 98US-087609P.
02-JUN-1998; 98US-087759P.
03-JUN-1998; 98US-087827P.
04-JUN-1998; 98US-088025P.
04-JUN-1998; 98US-088028P.
04-JUN-1998; 98US-088029P.
04-JUN-1998; 98US-088033P.
04-JUN-1998; 98US-088326P.
05-JUN-1998; 98US-088167P.
05-JUN-1998; 98US-088202P.
05-JUN-1998; 98US-088212P.
05-JUN-1998; 98US-088217P.
05-JUN-1998; 98US-088655P.
10-JUN-1998; 98US-088722P.
10-JUN-1998; 98US-088738P.
10-JUN-1998; 98US-088740P.
10-JUN-1998; 98US-088811P.
10-JUN-1998; 98US-088824P.
10-JUN-1998; 98US-088825P.
10-JUN-1998; 98US-088826P.
11-JUN-1998; 98US-088861P.
11-JUN-1998; 98US-088863P.
11-JUN-1998; 98US-088876P.
12-JUN-1998; 98US-089090P.
12-JUN-1998; 98US-089105P.
16-JUN-1998; 98US-089512P.
16-JUN-1998; 98US-089514P.
17-JUN-1998; 98US-089538P.
17-JUN-1998; 98US-089559P.
17-JUN-1998; 98US-089653P.
18-JUN-1998; 98US-089908P.
19-JUN-1998; 98US-089952P.
22-JUN-1998; 98US-090246P.
22-JUN-1998; 98US-090252P.
22-JUN-1998; 98US-090254P.
24-JUN-1998; 98US-090429P.
24-JUN-1998; 98US-090435P.
24-JUN-1998; 98US-090444P.
24-JUN-1998; 98US-090461P.
24-JUN-1998; 98US-090535P.
24-JUN-1998; 98US-090540P.
25-JUN-1998; 98US-090676P.
25-JUN-1998; 98US-090688P.
25-JUN-1998; 98US-090689P.
25-JUN-1998; 98US-090690P.
25-JUN-1998; 98US-090694P.
25-JUN-1998; 98US-090695P.
25-JUN-1998; 98US-090696P.
26-JUN-1998; 98US-090862P.
26-JUN-1998; 98US-090863P.
26-JUN-1998; 98US-091010P.
01-JUL-1998; 98US-091359P.
01-JUL-1998; 98US-091544P.
02-JUL-1998; 98US-091478P.
02-JUL-1998; 98US-091486P.
02-JUL-1998; 98US-091626P.
02-JUL-1998; 98US-091628P.
02-JUL-1998; 98US-091632P.
24-JUL-1998; 98US-094006P.
04-AUG-1998; 98US-095282P.
10-AUG-1998; 98US-095998P.
10-AUG-1998; 98US-096012P.
17-AUG-1998; 98US-096757P.

7-AUG-1998; 98US-096766P.
7-AUG-1998; 98US-096867P.
7-AUG-1998; 98US-096891P.
7-AUG-1998; 98US-096897P.
8-AUG-1998; 98US-096949P.
8-AUG-1998; 98US-096959P.
8-AUG-1998; 98US-097022P.
6-AUG-1998; 98US-097952P.
6-AUG-1998; 98US-097954P.
6-AUG-1998; 98US-097955P.
6-AUG-1998; 98US-097971P.
6-AUG-1998; 98US-097974P.
6-AUG-1998; 98US-098014P.
1-SEP-1998; 98US-098716P.
1-SEP-1998; 98US-098723P.
2-SEP-1998; 98US-098803P.
2-SEP-1998; 98US-098821P.
2-SEP-1998; 98US-098843P.
19-SEP-1998; 98US-099602P.
0-SEP-1998; 98US-099741P.
0-SEP-1998; 98US-099754P.
0-SEP-1998; 98US-099763P.
0-SEP-1998; 98US-099812P.
Y Match 100.0%; Score 119; DB 24; Length 119;
Local Similarity 100.0%; Pred. No. 3.3e-110; Indels 0; Gaps 0;
hes 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDQASRWLQEGGQCECKDWFRLAP 60
1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDQASRWLQEGGQCECKDWFRLAP 60
61 RKKFTVSGLPKQCPDHFKNVKTQHRRHKNKHSRACQFLKQCLRSFALPL 119
61 RKKFTVSGLPKQCPDHFKNVKTQHRRHKNKHSRACQFLKQCLRSFALPL 119
F 19
184
ABU59084 standard; Protein; 119 AA.
ABU59084;
28-APR-2003 (first entry)
Novel human secreted or transmembrane protein PRO842.
Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
cardiac insufficiency disorder; cancer; tumour; immune response;
adrenal cortical capillary endothelial growth; c-fos induction;
vascular endothelial growth factor inhibition; VEGF inhibition;
endothelial cell growth inhibitor; T-lymphocytes stimulation;
retinal neurons cell survival; rod photoreceptor cell survival;
retinal disorder; retinitis pigmentosa; kidney disorder;
mammalian kidney mesangial cell proliferation; Berger disease;
dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;
chondrocyte redifferentiation; sports injury; arthritis.
Homo sapiens.
US2002132252-A1.
19-SEP-2002.
14-NOV-2001; 2001US-0990442.
05-NOV-1997; 97WO-US20069.
16-SEP-1998; 98WO-US19330.
17-SEP-1998; 98WO-US19437.
07-OCT-1998; 98WO-US21141.
01-DEC-1998; 98WO-US25108.
05-JAN-1999; 99WO-US00106.
08-MAR-1999; 99WO-US05028.

PR 02-JUN-1999; 99WO-US12252.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 30-NOV-1999; 99WO-US28113.
PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 06-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US03376.
PR 11-FEB-2000; 2000WO-US03565.
PR 16-FEB-2000; 2000WO-US04341.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 15-MAY-2000; 2000WO-US13358.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 16-JUN-1997; 97US-049787P.
PR 17-OCT-1997; 97US-062250P.
PR 12-NOV-1997; 97US-065186P.
PR 13-NOV-1997; 97US-065311P.
PR 24-NOV-1997; 97US-066770P.
PR 25-FEB-1998; 98US-075945P.
PR 20-MAR-1998; 98US-078910P.
PR 28-APR-1998; 98US-083322P.
PR 07-MAY-1998; 98US-084600P.
PR 28-MAY-1998; 98US-087106P.
PR 02-JUN-1998; 98US-087607P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088021P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088026P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088030P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088734P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088742P.
PR 10-JUN-1998; 98US-088810P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088858P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089105P.

16-JUN-1998; 98US-089440P.
 16-JUN-1998; 98US-089512P.
 16-JUN-1998; 98US-089514P.
 17-JUN-1998; 98US-089532P.
 17-JUN-1998; 98US-089538P.
 17-JUN-1998; 98US-089598P.
 17-JUN-1998; 98US-089599P.
 17-JUN-1998; 98US-089600P.
 17-JUN-1998; 98US-089653P.
 18-JUN-1998; 98US-089801P.
 18-JUN-1998; 98US-089907P.
 18-JUN-1998; 98US-089908P.
 28-AUG-2001; 2001US-0941992.

(GETH) GENENTECH INC.

Askenazi AJ, Baker KP, Botstein D, Deenoyers L, Eaton DL;
 Ferrara NJ, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
 Grimaldi JC, Gurney AL, Kijavini IU, Napier MA, Pan J, Paoni NF;
 Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
 Zhang Z;

WPI; 2003-247083/24.
 N-PSDB; ABX80231.

Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346
 and PRO1375, which stimulate proliferation of stimulated T-lymphocytes
 are therapeutically useful for enhancing immune response and in cancer
 treatments

Claim 12; Fig 99; 648pp; English.

The invention describes an isolated human PRO polypeptide. The PRO
 polypeptides are useful in detecting PRO polypeptides in a sample, in
 linking a bioactive molecule to a cell expressing a PRO polypeptide, and
 in modulating at least one biological activity of a cell expressing a PRO
 polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus
 useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186
 stimulate adrenal cortical capillary endothelial growth, and PRO536,
 PRO943, PRO828, PRO1068 or PRO535, PRO826, PRO819, PRO1126,
 PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus
 useful for treating conditions or disorders where angiogenesis would be
 beneficial, e.g. wound healing and antagonist of this polypeptide are
 useful for treating cancerous tumours. PRO812 inhibits vascular
 endothelial growth factor (VEGF) stimulated proliferation of endothelial
 cells and is thus useful for inhibiting endothelial cell growth in
 mammals which would be beneficial in inhibiting tumour growth. PRO826,
 PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of
 stimulated T-lymphocytes and are therapeutically useful for enhancing
 immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of
 retinal neurons cells (PRO1132 is also enhances survival/proliferation of
 rod photoreceptor cells) and therefore are useful for treating retinal
 disorders of injuries, e.g. retinitis pigmentosa, AMD. PRO819, PRO813
 and PRO1066 induce proliferation of mammalian kidney mesangial cells,
 and therefore are useful for treating kidney disorders associated with
 decreased mesangial cell function such as Berger disease or other
 nephropathies associated with dermatitis, herpeticiformis or Crohn's
 disease. PRO1310, PRO844, PRO1312, PRO1182 and PRO1387 induce the
 proliferation and/or redifferentiation of chondrocytes in culture and
 are thus useful for treating sports injuries, and arthritis. This
 is the amino acid sequence of a novel human PRO protein.

Sequence 119 AA;

Very Match 100.0%; Score 119; DB 24; Length 119;
 at Local Similarity 100.0%; Pred. No. 3,3e-110; Gaps 0;
 iches 119; Conservative 0; Mismatches 0; Indels 0;

1 MKVLISLLILLPLMLMSVSSSLNFGVARGHRDQASRRWLQGGQCECKDWFRLAP 60

1 MKVLISLLILLPLMLMSVSSSLNFGVARGHRDQASRRWLQGGQCECKDWFRLAP 60

61 RRKEMTVSGLPKKQCPCDHFKGNVKKTRQHRHKNKHSRACQQLKQCQLRSFALPL 119

Db	61	RRKEMTVSGLPKKQCPCDHFKGNVKKTRQHRHKNKHSRACQQLKQCQLRSFALPL 119
RESULT 20		
ABUS9231		
ID	ABUS9231	standard; Protein; 119 AA.
XX	AC	ABUS9231;
XX	DT	22-APR-2003 (first entry)
XX	DE	Human secreted/transmembrane protein, #61.
XX	KW	Human; PRO; secreted; transmembrane; pharmaceutical;
XX	KW	diagnostic; biosensor; bioreactor; tumour; therapeutic;
XX	KW	gene therapy; tumour-associated antigenic target; TAP; ADEPT;
XX	OS	antibody-dependent enzyme mediated prodrug therapy; cytostatic.
XX	PN	Homo sapiens.
XX	PD	US2003027162-A1.
XX	PF	06-FEB-2003.
XX	PR	15-NOV-2001; 2001US-0997428.
XX	PR	05-NOV-1997; 97WO-US200069.
XX	PR	16-SEP-1998; 98WO-US19330.
XX	PR	17-SEP-1998; 98WO-US19437.
XX	PR	07-OCT-1998; 98WO-US21141.
XX	PR	01-DEC-1998; 98WO-US25108.
XX	PR	05-JAN-1999; 99WO-US00106.
XX	PR	08-MAR-1999; 99WO-US05028.
XX	PR	02-JUN-1999; 99WO-US12552.
XX	PR	15-SEP-1999; 99WO-US21090.
XX	PR	15-SEP-1999; 99WO-US21547.
XX	PR	30-NOV-1999; 99WO-US28313.
XX	PR	01-DEC-1999; 99WO-US28301.
XX	PR	01-DEC-1999; 99WO-US28634.
XX	PR	16-DEC-1999; 99WO-US30095.
XX	PR	20-DEC-1999; 99WO-US30911.
XX	PR	05-JAN-2000; 2000WO-US00219.
XX	PR	06-JAN-2000; 2000WO-US00376.
XX	PR	11-FEB-2000; 2000WO-US03565.
XX	PR	18-FEB-2000; 2000WO-US04341.
XX	PR	22-FEB-2000; 2000WO-US04414.
XX	PR	24-FEB-2000; 2000WO-US04914.
XX	PR	24-FEB-2000; 2000WO-US05004.
XX	PR	02-MAR-2000; 2000WO-US05841.
XX	PR	10-MAR-2000; 2000WO-US06319.
XX	PR	15-MAR-2000; 2000WO-US06884.
XX	PR	20-MAR-2000; 2000WO-US07377.
XX	PR	30-MAR-2000; 2000WO-US08439.
XX	PR	15-MAY-2000; 2000WO-US13358.
XX	PR	17-MAY-2000; 2000WO-US13705.
XX	PR	22-MAY-2000; 2000WO-US14042.
XX	PR	30-MAY-2000; 2000WO-US14941.
XX	PR	02-JUN-2000; 2000WO-US15264.
XX	PR	28-JUL-2000; 2000WO-US20710.
XX	PR	11-AUG-2000; 2000WO-US22031.
XX	PR	23-AUG-2000; 2000WO-US23522.
XX	PR	24-AUG-2000; 2000WO-US23328.
XX	PR	08-NOV-2000; 2000WO-US30952.
XX	PR	01-DEC-2000; 2000WO-US32678.
XX	PR	28-FEB-2001; 2001WO-US06520.
XX	PR	01-JUN-2001; 2001WO-US17800.
XX	PR	20-JUN-2001; 2001WO-US19692.
XX	PR	29-JUN-2001; 2001WO-US21066.
XX	PR	09-JUL-2001; 2001WO-US21735.
XX	PR	16-JUN-1997; 97US-049787P.
XX	PR	17-OCT-1997; 97US-062250P.
XX	PR	12-NOV-1997; 97US-065186P.

PR	01-JUL-1998;	97US-065311P;	98US-091544P;	01-JUL-1998;	98US-091544P;
PR	02-JUL-1998;	97US-065770P;	98US-091478P;	02-JUL-1998;	98US-091478P;
PR	03-JUL-1998;	97US-065770P;	98US-091519P;	03-JUL-1998;	98US-091519P;
PR	04-JUL-1998;	97US-065770P;	98US-091626P;	04-JUL-1998;	98US-091626P;
PR	05-JUL-1998;	97US-065770P;	98US-091628P;	05-JUL-1998;	98US-091628P;
PR	06-JUL-1998;	97US-065770P;	98US-091633P;	06-JUL-1998;	98US-091633P;
PR	07-JUL-1998;	97US-065770P;	98US-091646P;	07-JUL-1998;	98US-091646P;
PR	08-JUL-1998;	97US-065770P;	98US-091673P;	08-JUL-1998;	98US-091673P;
PR	09-JUL-1998;	97US-065770P;	98US-091778P;	09-JUL-1998;	98US-091778P;
PR	10-JUL-1998;	97US-065770P;	98US-091982P;	10-JUL-1998;	98US-091982P;
PR	11-JUL-1998;	97US-065770P;	98US-092182P;	11-JUL-1998;	98US-092182P;
PR	12-JUL-1998;	97US-065770P;	98US-092472P;	12-JUL-1998;	98US-092472P;
PR	13-JUL-1998;	97US-065770P;	98US-093339P;	13-JUL-1998;	98US-093339P;
PR	14-JUL-1998;	97US-065770P;	98US-094651P;	14-JUL-1998;	98US-094651P;
PR	15-JUL-1998;	97US-065770P;	98US-095282P;	15-JUL-1998;	98US-095282P;
PR	16-JUL-1998;	97US-065770P;	98US-095385P;	16-JUL-1998;	98US-095385P;
PR	17-JUL-1998;	97US-065770P;	98US-095501P;	17-JUL-1998;	98US-095501P;
PR	18-JUL-1998;	97US-065770P;	98US-095502P;	18-JUL-1998;	98US-095502P;
PR	19-JUL-1998;	97US-065770P;	98US-095318P;	19-JUL-1998;	98US-095318P;
PR	20-JUL-1998;	97US-065770P;	98US-095321P;	20-JUL-1998;	98US-095321P;
PR	21-JUL-1998;	97US-065770P;	98US-095325P;	21-JUL-1998;	98US-095325P;
PR	22-JUL-1998;	97US-065770P;	98US-095916P;	22-JUL-1998;	98US-095916P;
PR	23-JUL-1998;	97US-065770P;	98US-095929P;	23-JUL-1998;	98US-095929P;
PR	24-JUL-1998;	97US-065770P;	98US-096012P;	24-JUL-1998;	98US-096012P;
PR	25-JUL-1998;	97US-065770P;	98US-096143P;	25-JUL-1998;	98US-096143P;
PR	26-JUL-1998;	97US-065770P;	98US-096146P;	26-JUL-1998;	98US-096146P;
PR	27-JUL-1998;	97US-065770P;	98US-096329P;	27-JUL-1998;	98US-096329P;
PR	28-JUL-1998;	97US-065770P;	98US-096757P;	28-JUL-1998;	98US-096757P;
PR	29-JUL-1998;	97US-065770P;	98US-096766P;	29-JUL-1998;	98US-096766P;
PR	30-JUL-1998;	97US-065770P;	98US-096768P;	30-JUL-1998;	98US-096768P;
PR	31-JUL-1998;	97US-065770P;	98US-096773P;	31-JUL-1998;	98US-096773P;
PR	01-AUG-1998;	97US-065770P;	98US-096791P;	01-AUG-1998;	98US-096791P;
PR	02-AUG-1998;	97US-065770P;	98US-096867P;	02-AUG-1998;	98US-096867P;
PR	03-AUG-1998;	97US-065770P;	98US-096891P;	03-AUG-1998;	98US-096891P;
PR	04-AUG-1998;	97US-065770P;	98US-096894P;	04-AUG-1998;	98US-096894P;
PR	05-AUG-1998;	97US-065770P;	98US-096895P;	05-AUG-1998;	98US-096895P;
PR	06-AUG-1998;	97US-065770P;	98US-096897P;	06-AUG-1998;	98US-096897P;
PR	07-AUG-1998;	97US-065770P;	98US-096949P;	07-AUG-1998;	98US-096949P;
PR	08-AUG-1998;	97US-065770P;	98US-096950P;	08-AUG-1998;	98US-096950P;
PR	09-AUG-1998;	97US-065770P;	98US-096959P;	09-AUG-1998;	98US-096959P;
PR	10-AUG-1998;	97US-065770P;	98US-096960P;	10-AUG-1998;	98US-096960P;
PR	11-AUG-1998;	97US-065770P;	98US-097022P;	11-AUG-1998;	98US-097022P;
PR	12-AUG-1998;	97US-065770P;	98US-097141P;	12-AUG-1998;	98US-097141P;
PR	13-AUG-1998;	97US-065770P;	98US-097218P;	13-AUG-1998;	98US-097218P;
PR	14-AUG-1998;	97US-065770P;	98US-097661P;	14-AUG-1998;	98US-097661P;
PR	15-AUG-1998;	97US-065770P;	98US-097952P;	15-AUG-1998;	98US-097952P;
PR	16-AUG-1998;	97US-065770P;	98US-097954P;	16-AUG-1998;	

T 21

380

ABU59380 standard; Protein; 119 AA.

ABU59380;

22-APR-2003 (first entry)

Novel human secreted or transmembrane protein PRO839.

Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing; cardiac insufficiency disorder; cancer; tumour; immune response; adrenal cortical capillary endothelial growth; c-fos induction; vascular endothelial growth factor inhibition; VEGF inhibition; endothelial cell growth inhibitor; T-lymphocytes stimulation; retinal neurons cell survival; rod photoreceptor cell survival; retinal disorder; retinitis pigmentosa; kidney disorder; mammalian kidney mesangial cell proliferation; Berger disease; dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation; chondrocyte redifferentiation; sports injury; arthritis.

Homo sapiens.

US2003027985-A1.

06-FEB-2003.

14-NOV-2001; 2001US-0390562.

05-NOV-1997; 97WO-US200069.

16-SEP-1998; 98WO-US19330.

17-SEP-1998; 98WO-US19437.

07-OCT-1998; 98WO-US21141.

01-DEC-1998; 98WO-US25108.

05-JAN-1999; 99WO-US00106.

08-MAR-1999; 99WO-US05028.

02-JUN-1999; 99WO-US12252.

15-SEP-1999; 99WO-US21090.

15-SEP-1999; 99WO-US21547.

30-NOV-1999; 99WO-US28313.

01-DEC-1999; 99WO-US28301.

01-DEC-1999; 99WO-US28334.

16-DEC-1999; 99WO-US30095.

20-DEC-1999; 99WO-US30911.

05-JAN-2000; 2000WO-US00219.

06-JAN-2000; 2000WO-US00376.

11-FEB-2000; 2000WO-US03565.

18-FEB-2000; 2000WO-US04341.

22-FEB-2000; 2000WO-US04414.

24-FEB-2000; 2000WO-US04914.

24-FEB-2000; 2000WO-US05004.

02-MAR-2000; 2000WO-US05941.

10-MAR-2000; 2000WO-US06319.

15-MAR-2000; 2000WO-US06884.

20-MAR-2000; 2000WO-US07377.

30-MAR-2000; 2000WO-US08439.

15-MAY-2000; 2000WO-US13358.

17-MAY-2000; 2000WO-US13705.

22-MAY-2000; 2000WO-US14042.

30-MAY-2000; 2000WO-US14941.

02-JUN-2000; 2000WO-US15264.

28-JUL-2000; 2000WO-US20710.

11-AUG-2000; 2000WO-US22031.

23-AUG-2000; 2000WO-US23522.

24-AUG-2000; 2000WO-US23328.

08-NOV-2000; 2000WO-US30952.

01-DEC-2000; 2000WO-US32678.

28-FEB-2001; 2001WO-US06820.

01-JUN-2001; 2001WO-US17800.

20-JUN-2001; 2001WO-US19692.

29-JUN-2001; 2001WO-US21066.

09-JUL-2001; 2001WO-US21735.

PR 16-JUN-1997; 97US-049787P.
 PR 17-OCT-1997; 97US-062250P.
 PR 12-NOV-1997; 97US-065186P.
 PR 13-NOV-1997; 97US-065311P.
 PR 24-NOV-1997; 97US-066770P.
 PR 25-FEB-1998; 98US-075945P.
 PR 20-MAR-1998; 98US-078910P.
 PR 28-APR-1998; 98US-083322P.
 PR 07-MAY-1998; 98US-084600P.
 PR 28-MAY-1998; 98US-087106P.
 PR 02-JUN-1998; 98US-087607P.
 PR 02-JUN-1998; 98US-087609P.
 PR 02-JUN-1998; 98US-087759P.
 PR 03-JUN-1998; 98US-087827P.
 PR 04-JUN-1998; 98US-088021P.
 PR 04-JUN-1998; 98US-088025P.
 PR 04-JUN-1998; 98US-088026P.
 PR 04-JUN-1998; 98US-088028P.
 PR 04-JUN-1998; 98US-088029P.
 PR 04-JUN-1998; 98US-088030P.
 PR 04-JUN-1998; 98US-088033P.
 PR 05-JUN-1998; 98US-088326P.
 PR 05-JUN-1998; 98US-088167P.
 PR 05-JUN-1998; 98US-088202P.
 PR 05-JUN-1998; 98US-088212P.
 PR 05-JUN-1998; 98US-088217P.
 PR 09-JUN-1998; 98US-088655P.
 PR 10-JUN-1998; 98US-088734P.
 PR 10-JUN-1998; 98US-088738P.
 PR 10-JUN-1998; 98US-088742P.
 PR 10-JUN-1998; 98US-088810P.
 PR 10-JUN-1998; 98US-088824P.
 PR 10-JUN-1998; 98US-088826P.
 PR 11-JUN-1998; 98US-088858P.
 PR 11-JUN-1998; 98US-088861P.
 PR 11-JUN-1998; 98US-088876P.
 PR 12-JUN-1998; 98US-089105P.
 PR 16-JUN-1998; 98US-089440P.
 PR 16-JUN-1998; 98US-089512P.
 PR 16-JUN-1998; 98US-089514P.
 PR 16-JUN-1998; 98US-089532P.
 PR 17-JUN-1998; 98US-089538P.
 PR 17-JUN-1998; 98US-089598P.
 PR 17-JUN-1998; 98US-089599P.
 PR 17-JUN-1998; 98US-089600P.
 PR 17-JUN-1998; 98US-089653P.
 PR 18-JUN-1998; 98US-089901P.
 PR 18-JUN-1998; 98US-089907P.
 PR 19-JUN-1998; 98US-089908P.
 PR 19-JUN-1998; 98US-089947P.
 PR 19-JUN-1998; 98US-089946P.
 PR 22-JUN-1998; 98US-090252P.
 PR 22-JUN-1998; 98US-090254P.
 PR 22-JUN-1998; 98US-090254P.
 PR 23-JUN-1998; 98US-090349P.
 PR 23-JUN-1998; 98US-090355P.
 PR 24-JUN-1998; 98US-090429P.
 PR 24-JUN-1998; 98US-090431P.
 PR 24-JUN-1998; 98US-090435P.
 PR 24-JUN-1998; 98US-090444P.
 PR 24-JUN-1998; 98US-090445P.
 PR 24-JUN-1998; 98US-090472P.
 PR 24-JUN-1998; 98US-090535P.
 PR 24-JUN-1998; 98US-090540P.
 PR 24-JUN-1998; 98US-090542P.
 PR 24-JUN-1998; 98US-090557P.
 PR 25-JUN-1998; 98US-090676P.
 PR 25-JUN-1998; 98US-090678P.
 PR 25-JUN-1998; 98US-090690P.
 PR 25-JUN-1998; 98US-090694P.
 PR 25-JUN-1998; 98US-090695P.
 PR 25-JUN-1998; 98US-090696P.

16-JUN-1998;	98US-090862P.	ID	ABU60515 standard; Protein; 119 AA.
16-JUN-1998;	98US-090863P.	XX	
1-JUL-1998;	98US-091360P.	AC	ABU60515;
1-JUL-1998;	98US-091544P.	XX	
2-JUL-1998;	98US-091478P.	DT	01-MAY-2003 (first entry)
12-JUL-1998;	98US-091519P.	XX	
12-JUL-1998;	98US-091626P.	DE	Human secreted/transmembrane protein, #61.
12-JUL-1998;	98US-091628P.	XX	
12-JUL-1998;	98US-091633P.	XX	Human; PRO; secreted; transmembrane; signal peptide;
12-JUL-1998;	98US-091646P.	KW	pharmaceutical; diagnostic; therapeutic; gene therapy.
12-JUL-1998;	98US-091673P.	XX	
17-JUL-1998;	98US-091578P.	OS	Homo sapiens.
17-JUL-1998;	98US-091582P.	XX	
19-JUL-1998;	98US-092182P.	PN	US2002160384-A1.
0-JUL-1998;	98US-092472P.	XX	
10-JUL-1998;	98US-093339P.	PD	31-OCT-2002.
10-JUL-1998;	98US-094651P.	XX	
14-AUG-1998;	98US-095282P.	PF	14-NOV-2001; 2001US-0992598.
14-AUG-1998;	98US-095285P.	XX	
14-AUG-1998;	98US-095301P.	XX	
14-AUG-1998;	98US-095302P.	PR	05-NOV-1997; 97WO-US20069.
14-AUG-1998;	98US-095318P.	PR	16-SEP-1998; 98WO-US19330.
14-AUG-1998;	98US-095321P.	PR	17-SEP-1998; 98WO-US19437.
14-AUG-1998;	98US-095325P.	PR	07-OCT-1998; 98WO-US21141.
0-AUG-1998;	98US-095316P.	PR	01-DEC-1998; 98WO-US25108.
10-AUG-1998;	98US-095329P.	PR	05-JAN-1999; 99WO-US00106.
10-AUG-1998;	98US-086112P.	PR	08-MAR-1999; 99WO-US05028.
11-AUG-1998;	98US-096143P.	PR	02-JUN-1999; 99WO-US12252.
12-AUG-1998;	98US-096346P.	PR	15-SEP-1999; 99WO-US21090.
12-AUG-1998;	98US-096329P.	PR	15-SEP-1999; 99WO-US21547.
17-AUG-1998;	98US-096757P.	PR	30-NOV-1999; 99WO-US28301.
17-AUG-1998;	98US-096766P.	PR	01-DEC-1999; 99WO-US28634.
17-AUG-1998;	98US-096773P.	PR	16-DEC-1999; 99WO-US30095.
17-AUG-1998;	98US-096791P.	PR	20-DEC-1999; 99WO-US30911.
17-AUG-1998;	98US-096891P.	PR	05-JAN-2000; 2000WO-US00219.
17-AUG-1998;	98US-096895P.	PR	06-JAN-2000; 2000WO-US00376.
17-AUG-1998;	98US-096897P.	PR	11-FEB-2000; 2000WO-US03565.
18-AUG-1998;	98US-096894P.	PR	18-FEB-2000; 2000WO-US04341.
18-AUG-1998;	98US-096897P.	PR	22-FEB-2000; 2000WO-US04414.
18-AUG-1998;	98US-096949P.	PR	24-FEB-2000; 2000WO-US04914.
18-AUG-1998;	98US-096950P.	PR	24-FEB-2000; 2000WO-US05004.
18-AUG-1998;	98US-096959P.	PR	02-MAR-2000; 2000WO-US05841.
18-AUG-1998;	98US-097022P.	PR	10-MAR-2000; 2000WO-US06319.
19-AUG-1998;	98US-097141P.	PR	15-MAR-2000; 2000WO-US06884.
20-AUG-1998;	98US-097218P.	PR	20-MAR-2000; 2000WO-US07377.
24-AUG-1998;	98US-097661P.	PR	30-MAR-2000; 2000WO-US08439.
26-AUG-1998;	98US-097952P.	PR	15-MAY-2000; 2000WO-US13358.
26-AUG-1998;	98US-097954P.	PR	17-MAY-2000; 2000WO-US13705.
26-AUG-1998;	98US-097955P.	PR	22-MAY-2000; 2000WO-US14042.
26-AUG-1998;	98US-097971P.	PR	30-MAY-2000; 2000WO-US14941.
26-AUG-1998;	98US-097974P.	PR	02-JUN-2000; 2000WO-US15264.
26-AUG-1998;	98US-097978P.	PR	28-JUL-2000; 2000WO-US20710.
26-AUG-1998;	98US-097979P.	PR	11-AUG-2000; 2000WO-US22031.
26-AUG-1998;	98US-097986P.	PR	23-AUG-2000; 2000WO-US23522.
26-AUG-1998;	98US-098014P.	PR	24-AUG-2000; 2000WO-US23328.
		PR	08-NOV-2000; 2000WO-US30952.
		PR	01-DEC-2000; 2000WO-US32678.
		PR	28-FEB-2001; 2001WO-US06520.
		PR	01-JUN-2001; 2001WO-US17800.
		PR	20-JUN-2001; 2001WO-US19692.
		PR	29-JUN-2001; 2001WO-US21066.
		PR	09-JUL-2001; 2001WO-US21735.
		PR	16-JUN-1997; 97US-049787P.
		PR	17-OCT-1997; 97US-062250P.
		PR	12-NOV-1997; 97US-065186P.
		PR	13-NOV-1997; 97US-065311P.
		PR	24-NOV-1997; 97US-066770P.
		PR	25-FEB-1998; 98US-075945P.
		PR	20-MAR-1998; 98US-078910P.
		PR	28-APR-1998; 98US-083322P.
		PR	07-MAY-1998; 98US-084600P.
		PR	28-MAY-1998; 98US-087106P.
		PR	02-JUN-1998; 98US-087607P.

ry Match 100.0%; Score 119; DB 24; Length 119;

t Local Similarity 100.0%; Pred. No. 3.3e-110;

ches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 MKVLISLLLLLPLMLSMVSSSLNPGVARGHEDRCQASRWLQSGGCECKDWFLRAP 60

1 MKVLISLLLLLPLMLSMVSSSLNPGVARGHEDRCQASRWLQSGGCECKDWFLRAP 60

61 RRKFMTVSGLPKQCPDHFPGKGVNKKTRHQRHHRKKNKHSRACQFLKQCQLRSFALPL 119

51 RRKFMTVSGLPKQCPDHFPGKGVNKKTRHQRHHRKKNKHSRACQFLKQCQLRSFALPL 119

format from USPTO at seqdata.uspto.gov/sequence.html.

CC 98US-087609P.
XX 98US-087759P.
SQ 98US-087827P.
Sequence 119 AA;
Query Match 100.0%; Score 119; DB 24; Length 119;
Best Local Similarity 100.0%; Pred. No. 3.3e-110;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDRGQASRRWLQEGGQCECKDWFLRAP 60
DB 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDRGQASRRWLQEGGQCECKDWFLRAP 60
QY 61 RRKEMTVSGLPKQPCDHPKGNVKKTRHQHRRKNSRACQQLKQCOLRSFALPL 119
DB 61 RRKEMTVSGLPKQPCDHPKGNVKKTRHQHRRKNSRACQQLKQCOLRSFALPL 119

RESULT 23
ABUS8006
ID ABUS8006 standard; Protein; 119 AA.
XX
AC ABUS8006;
XX
DT 14-APR-2003 (first entry)
XX
DE Human PRO polypeptide #38.
XX
KW Human; PRO; cytostatic; tumour; cancer; breast; lung; stomach; liver;
horse; cow; dog; cat; sheep; pig; goat; rabbit; ADEPT;
antibody-dependent enzyme mediated prodrug therapy.
XX
OS Homo sapiens.
XX
PN US2003027163-A1.
XX
PD 06-FEB-2003.
XX
PF 15-NOV-2001; 2001US-0997666.
XX
PR 05-NOV-1997; 97WO-US20069.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 05-JAN-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 02-JUN-1999; 99WO-US12252.
PR 15-SEP-1999; 99WO-US1090.
PR 15-SEP-1999; 99WO-US21547.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 16-DEC-1999; 99WO-US28634.
PR 20-DEC-1999; 99WO-US30911.
PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 15-MAY-2000; 2000WO-US13358.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.

02-JUN-1998; 98US-087609P.
02-JUN-1998; 98US-087759P.
03-JUN-1998; 98US-087827P.
04-JUN-1998; 98US-088021P.
04-JUN-1998; 98US-088025P.
04-JUN-1998; 98US-088026P.
04-JUN-1998; 98US-088028P.
04-JUN-1998; 98US-088029P.
04-JUN-1998; 98US-088030P.
04-JUN-1998; 98US-088033P.
04-JUN-1998; 98US-088326P.
05-JUN-1998; 98US-088167P.
05-JUN-1998; 98US-088202P.
05-JUN-1998; 98US-088212P.
05-JUN-1998; 98US-088217P.
09-JUN-1998; 98US-088655P.
10-JUN-1998; 98US-088734P.
10-JUN-1998; 98US-088738P.
10-JUN-1998; 98US-088742P.
10-JUN-1998; 98US-088810P.
10-JUN-1998; 98US-088824P.
10-JUN-1998; 98US-088826P.
11-JUN-1998; 98US-088858P.
11-JUN-1998; 98US-088861P.
11-JUN-1998; 98US-088876P.
12-JUN-1998; 98US-089105P.
16-JUN-1998; 98US-089440P.
16-JUN-1998; 98US-089512P.
16-JUN-1998; 98US-089514P.
17-JUN-1998; 98US-089532P.
17-JUN-1998; 98US-089538P.
17-JUN-1998; 98US-089598P.
17-JUN-1998; 98US-089599P.
17-JUN-1998; 98US-089600P.
17-JUN-1998; 98US-089653P.
18-JUN-1998; 98US-089801P.
18-JUN-1998; 98US-089907P.
18-JUN-1998; 98US-089908P.
28-AUG-2001; 2001US-0941992.

(GETH) GENENTECH INC.

Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
Ferrara N, Fong S, Gerber H, Gertschen ME, Goddard A, Godowski EU;
Grimaldi JC, Gurney AL, Kijavini IJ, Napier MA, Pan J, Paoni NF;
Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PW, Wood WI;
Zhang Z;

WPI: 2003-288106/28.
N-PSDB; ABX90209.

New transmembrane polypeptides and nucleic acids encoding the polypeptides, useful in gene therapy, in chromosome identification, as chromosome markers, or in generating probes -

Claim 12; Fig 99; 650pp; English.

The invention discloses isolated PRO secreted/transmembrane polypeptides comprising a sequence without signal peptide and the nucleic acid encoding them. The polypeptides can be used to raise antibodies that specifically bind to the PRO polypeptide, for linking a bioactive molecule to a cell expressing a PRO protein and for modulating at least one biological activity of a cell. The PRO polypeptides or polynucleotides are also useful in gene therapy, in chromosome identification, as chromosome markers, or in generating probes. The PRO polypeptides are useful as molecular markers for protein electrophoresis, and the isolated nucleic acids may be used for recombinantly expressing those markers. The PRO polypeptides and nucleic acids may also be used in tissue typing. Anti-PRO antibodies are useful in diagnostic assays for PRO, and in affinity purification of PRO from recombinant cell culture or natural sources. The sequences presented in ABJ60478-ABJ60624 are the PRO polynucleotides of the invention.

Note: The sequence data for this patent is also available in electronic

ary Match 100.0%; Score 119; DB 24; Length 119;
at Local Similarity 100.0%; Pred. No. 3.3e-110;
:ches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
1 MKVLISLILLPLMLSMVSSSLNPGVARGHRDRQASRRWLQGGQECCKDWFRLAP 60
1 MKVLISLILLPLMLSMVSSSLNPGVARGHRDRQASRRWLQGGQECCKDWFRLAP 60
61 RRKFTVSGLPKQCPDHPKGNVKKTRQHRHKPNKHSRACQFLKQCOLRSPALPL 119
61 RRKFTVSGLPKQCPDHPKGNVKKTRQHRHKPNKHSRACQFLKQCOLRSPALPL 119

LT 24

8469

ABUS8469 standard; Protein; 119 AA.

ABUS8469;

15-APR-2003 (first entry)

Human PRO polypeptide #70.

Human; PRO; cytostatic; tumour; cancer; breast; lung; stomach;
liver; dog; cat; cow; horse; sheep; pig; goat; rabbit; ADEPT;
antibody-dependent enzyme mediated prodrug therapy.

Homo sapiens.

US2003027272-A1.

06-FEB-2003.

21-JUN-2002; 2002US-0176492.

16-SEP-1998; 98WO-US19330.
07-OCT-1998; 98WO-US21141.
01-DEC-1998; 98WO-US25108.
08-MAR-1999; 99WO-US05028.
10-MAR-1999; 99WO-US05190.
14-MAY-1999; 99WO-US10733.
02-JUN-1999; 99WO-US12252.
01-SEP-1999; 99WO-US20111.
15-SEP-1999; 99WO-US21090.
30-NOV-1999; 99WO-US28313.
01-DEC-1999; 99WO-US28301.
02-DEC-1999; 99WO-US28551.
30-DEC-1999; 99WO-US31274.
05-JAN-2000; 2000WO-US00219.
18-FEB-2000; 2000WO-US04341.
18-FEB-2000; 2000WO-US04342.
22-FEB-2000; 2000WO-US04414.
24-FEB-2000; 2000WO-US05004.
01-MAR-2000; 2000WO-US05601.
02-MAR-2000; 2000WO-US05841.
10-MAR-2000; 2000WO-US06319.
15-MAR-2000; 2000WO-US06884.
30-MAR-2000; 2000WO-US08439.
17-MAY-2000; 2000WO-US13705.
22-MAY-2000; 2000WO-US14042.
30-MAY-2000; 2000WO-US14941.
02-JUN-2000; 2000WO-US15264.
28-JUL-2000; 2000WO-US20710.
24-AUG-2000; 2000WO-US23328.
08-NOV-2000; 2000WO-US30952.
10-NOV-2000; 2000WO-US30873.
01-DEC-2000; 2000WO-US32678.
20-DEC-2000; 2000WO-US34956.
28-FEB-2001; 2001WO-US06520.
01-JUN-2001; 2001WO-US17800.
20-JUN-2001; 2001WO-US19692.
29-JUN-2001; 2001WO-US21066.

PR 09-JUL-2001; 2001WO-US21735.
PR 18-SEP-1997; 97US-059263P.
PR 18-SEP-1997; 97US-059266P.
PR 17-OCT-1997; 97US-062250P.
PR 21-OCT-1997; 97US-063486P.
PR 24-OCT-1997; 97US-063120P.
PR 24-OCT-1997; 97US-063121P.
PR 28-OCT-1997; 97US-063540P.
PR 28-OCT-1997; 97US-063541P.
PR 28-OCT-1997; 97US-063544P.
PR 28-OCT-1997; 97US-063564P.
PR 29-OCT-1997; 97US-063734P.
PR 31-OCT-1997; 97US-063870P.
PR 31-OCT-1997; 97US-064103P.
PR 13-NOV-1997; 97US-065311P.
PR 21-NOV-1997; 97US-066120P.
PR 24-NOV-1997; 97US-066468P.
PR 24-NOV-1997; 97US-066772P.
PR 11-DEC-1997; 97US-069335P.
PR 12-DEC-1997; 97US-069425P.
PR 17-DEC-1997; 97US-069870P.
PR 18-DEC-1997; 97US-068017P.
PR 10-MAR-1998; 98US-077450P.
PR 11-MAR-1998; 98US-077632P.
PR 11-MAR-1998; 98US-077643P.
PR 20-MAR-1998; 98US-078886P.
PR 20-MAR-1998; 98US-078939P.
PR 27-MAR-1998; 98US-079664P.
PR 27-MAR-1998; 98US-079786P.
PR 31-MAR-1998; 98US-080107P.
PR 31-MAR-1998; 98US-080194P.
PR 01-APR-1998; 98US-080327P.
PR 01-APR-1998; 98US-080333P.
PR 08-APR-1998; 98US-081049P.
PR 08-APR-1998; 98US-081070P.
PR 09-APR-1998; 98US-081195P.
PR 15-APR-1998; 98US-081838P.
PR 21-APR-1998; 98US-082568P.
PR 21-APR-1998; 98US-082569P.
PR 22-APR-1998; 98US-082704P.
PR 22-APR-1998; 98US-082797P.
PR 28-APR-1998; 98US-083322P.
PR 29-APR-1998; 98US-083495P.
PR 29-APR-1998; 98US-083496P.
PR 29-APR-1998; 98US-083499P.
PR 29-APR-1998; 98US-083559P.
PR 05-MAY-1998; 98US-084366P.
PR 06-MAY-1998; 98US-084414P.
PR 07-MAY-1998; 98US-084639P.
PR 07-MAY-1998; 98US-084640P.
PR 07-MAY-1998; 98US-084643P.
PR 15-MAY-1998; 98US-085579P.
PR 15-MAY-1998; 98US-085580P.
PR 15-MAY-1998; 98US-085582P.
PR 15-MAY-1998; 98US-085700P.
PR 18-MAY-1998; 98US-086023P.
PR 22-MAY-1998; 98US-086392P.
PR 22-MAY-1998; 98US-086486P.
PR 28-MAY-1998; 98US-087098P.
PR 28-MAY-1998; 98US-087208P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.

0-JUN-1998;	98US-0887222P.	Matches 119;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
0-JUN-1998;	98US-088738P.					
0-JUN-1998;	98US-088740P.					
0-JUN-1998;	98US-088811P.					
0-JUN-1998;	98US-088824P.					
0-JUN-1998;	98US-088825P.					
0-JUN-1998;	98US-088826P.					
1-JUN-1998;	98US-088861P.					
1-JUN-1998;	98US-088863P.					
1-JUN-1998;	98US-088876P.					
2-JUN-1998;	98US-089000P.					
2-JUN-1998;	98US-089105P.					
6-JUN-1998;	98US-089512P.					
6-JUN-1998;	98US-089514P.					
7-JUN-1998;	98US-089538P.					
7-JUN-1998;	98US-089598P.					
7-JUN-1998;	98US-089653P.					
8-JUN-1998;	98US-089908P.					
9-JUN-1998;	98US-089952P.					
12-JUN-1998;	98US-090246P.					
12-JUN-1998;	98US-090252P.					
12-JUN-1998;	98US-090254P.					
14-JUN-1998;	98US-090429P.					
14-JUN-1998;	98US-090435P.					
14-JUN-1998;	98US-090444P.					
14-JUN-1998;	98US-090461P.					
14-JUN-1998;	98US-090535P.					
14-JUN-1998;	98US-090540P.					
25-JUN-1998;	98US-090676P.					
25-JUN-1998;	98US-090679P.					
25-JUN-1998;	98US-090688P.					
25-JUN-1998;	98US-090690P.					
25-JUN-1998;	98US-090694P.					
25-JUN-1998;	98US-090695P.					
26-JUN-1998;	98US-090696P.					
26-JUN-1998;	98US-090862P.					
26-JUN-1998;	98US-090863P.					
26-JUN-1998;	98US-091010P.					
01-JUL-1998;	98US-091359P.					
01-JUL-1998;	98US-091544P.					
02-JUL-1998;	98US-091478P.					
02-JUL-1998;	98US-091486P.					
02-JUL-1998;	98US-091628P.					
02-JUL-1998;	98US-091628P.					
02-JUL-1998;	98US-091632P.					
04-AUG-1998;	98US-094006P.					
10-AUG-1998;	98US-095282P.					
10-AUG-1998;	98US-095282P.					
10-AUG-1998;	98US-096012P.					
17-AUG-1998;	98US-096757P.					
17-AUG-1998;	98US-096766P.					
17-AUG-1998;	98US-096867P.					
17-AUG-1998;	98US-096891P.					
17-AUG-1998;	98US-096897P.					
18-AUG-1998;	98US-096949P.					
18-AUG-1998;	98US-096959P.					
18-AUG-1998;	98US-097022P.					
26-AUG-1998;	98US-097952P.					
26-AUG-1998;	98US-097954P.					
26-AUG-1998;	98US-097955P.					
26-AUG-1998;	98US-097971P.					
26-AUG-1998;	98US-097974P.					
26-AUG-1998;	98US-098014P.					
01-SEP-1998;	98US-099716P.					
01-SEP-1998;	98US-098723P.					
02-SEP-1998;	98US-098803P.					
02-SEP-1998;	98US-098821P.					
02-SEP-1998;	98US-098843P.					
09-SEP-1998;	98US-099602P.					
10-SEP-1998;	98US-099741P.					
xy Match	Score 119;	DB 24;	Length 119;			
it Local Similarity	100.0%;		Pred. No. 3.3e-110;			

QY	1	MKVLISSLLLLLPLMLMSVSSSLNPGVARGHSDRGQASRRMLQEGQCECKDWFIRAP	60
Db	1	MKVLISSLLLLLPLMLMSVSSSLNPGVARGHSDRGQASRRMLQEGQCECKDWFIRAP	60
QY	61	RKFKMTUSGLPKKQPCDHPKGNVKKTRHORHHRKPNKHSRACQQLKQCQLRSFALPL	119
Db	61	RKFKMTUSGLPKKQPCDHPKGNVKKTRHORHHRKPNKHSRACQQLKQCQLRSFALPL	119
RESULT 25			
ABUS8937			
ID	ABUS8937	standard; Protein; 119 AA.	
XX			
AC	ABUS8937;		
XX			
DT	16-APR-2003	(first entry)	
XX			
DE		Human secreted/transmembrane protein, #61.	
XX			
KW		Human; PRO; secreted; transmembrane; signal peptide;	
KW		pharmaceutical; diagnostic; biosensor; bioreactor; tumour; therapeutic;	
KW		colon cancer; lung cancer; breast cancer; cancer; gene therapy.	
OS		Homo sapiens.	
XX			
PN		US2002142961-A1.	
XX			
PD		03-OCT-2002.	
XX			
PF		19-NOV-2001; 2001US-0989721.	
PR		05-NOV-1997; 97WO-US20069.	
PR		17-SEP-1998; 98WO-US19437.	
PR		07-OCT-1998; 98WO-US21141.	
PR		01-DEC-1998; 98WO-US25108.	
PR		05-JAN-1999; 99WO-US00106.	
PR		08-MAR-1999; 99WO-US05028.	
PR		02-JUN-1999; 99WO-US12252.	
PR		15-SEP-1999; 99WO-US21090.	
PR		15-SEP-1999; 99WO-US21547.	
PR		30-NOV-1999; 99WO-US28313.	
PR		01-DEC-1999; 99WO-US28301.	
PR		01-DEC-1999; 99WO-US28634.	
PR		16-DEC-1999; 99WO-US30095.	
PR		20-DEC-1999; 99WO-US30911.	
PR		05-JAN-2000; 2000WO-US00219.	
PR		06-JAN-2000; 2000WO-US00376.	
PR		11-FEB-2000; 2000WO-US03565.	
PR		18-FEB-2000; 2000WO-US04341.	
PR		22-FEB-2000; 2000WO-US0414.	
PR		24-FEB-2000; 2000WO-US04914.	
PR		24-FEB-2000; 2000WO-US05004.	
PR		02-MAR-2000; 2000WO-US05841.	
PR		10-MAR-2000; 2000WO-US06319.	
PR		15-MAR-2000; 2000WO-US06884.	
PR		20-MAR-2000; 2000WO-US07377.	
PR		30-MAR-2000; 2000WO-US08439.	
PR		15-MAY-2000; 2000WO-US13358.	
PR		17-MAY-2000; 2000WO-US13705.	
PR		22-MAY-2000; 2000WO-US14042.	
PR		30-MAY-2000; 2000WO-US14941.	
PR		02-JUN-2000; 2000WO-US15264.	
PR		28-JUL-2000; 2000WO-US20710.	
PR		11-AUG-2000; 2000WO-US22031.	
PR		23-AUG-2000; 2000WO-US23522.	
PR		24-AUG-2000; 2000WO-US23328.	
PR		08-NOV-2000; 2000WO-US30952.	
PR		01-DEC-2000; 2000WO-US32678.	
PR		28-FEB-2001; 2001WO-US06520.	
PR		01-JUN-2001; 2001WO-US17800.	
PR		20-JUN-2001; 2001WO-US19692.	

29-JUN-2001; 2001WO-US21066.
09-JUL-2001; 2001WO-US21735.
16-JUN-1997; 97US-049787P.
17-OCT-1997; 97US-062250P.
12-NOV-1997; 97US-065186P.
13-NOV-1997; 97US-065311P.
24-NOV-1997; 97US-068770P.
25-FEB-1998; 98US-075945P.
20-MAR-1998; 98US-078910P.
28-APR-1998; 98US-083322P.
07-MAY-1998; 98US-084600P.
28-MAY-1998; 98US-087106P.
02-JUN-1998; 98US-087607P.
02-JUN-1998; 98US-087609P.
02-JUN-1998; 98US-087759P.
03-JUN-1998; 98US-087827P.
04-JUN-1998; 98US-088021P.
04-JUN-1998; 98US-088025P.
04-JUN-1998; 98US-088026P.
04-JUN-1998; 98US-088028P.
04-JUN-1998; 98US-088029P.
04-JUN-1998; 98US-088030P.
04-JUN-1998; 98US-088033P.
04-JUN-1998; 98US-088326P.
05-JUN-1998; 98US-088167P.
05-JUN-1998; 98US-088202P.
05-JUN-1998; 98US-088212P.
05-JUN-1998; 98US-088217P.
09-JUN-1998; 98US-088655P.
10-JUN-1998; 98US-088734P.
10-JUN-1998; 98US-088738P.
10-JUN-1998; 98US-088742P.
10-JUN-1998; 98US-088810P.
10-JUN-1998; 98US-088824P.
10-JUN-1998; 98US-088826P.
11-JUN-1998; 98US-088858P.
11-JUN-1998; 98US-088861P.
11-JUN-1998; 98US-088876P.
12-JUN-1998; 98US-089105P.
12-JUN-1998; 98US-089440P.
16-JUN-1998; 98US-089512P.
16-JUN-1998; 98US-089514P.
17-JUN-1998; 98US-089532P.
17-JUN-1998; 98US-089538P.
17-JUN-1998; 98US-089598P.
17-JUN-1998; 98US-089599P.
17-JUN-1998; 98US-089600P.
17-JUN-1998; 98US-089653P.
18-JUN-1998; 98US-089801P.
18-JUN-1998; 98US-089907P.
18-JUN-1998; 98US-089908P.
28-AUG-2001; 2001US-0941992.

(GETH) GENENTECH INC.

Ashkenazi AJ, Baker KP, Borstein D, Desnoyers L, Eaton DL;
Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PU;
Grimaldi JC, Gurney AL, Kijavini IJ, Napier MA, Pan J, Paoni NF;
Roy MA, Stewart TA, Tamas D, Watanabe CK, Williams PM, Wood WT;
Zhang Z;

WPI; 2003-155950/15.

New secreted and transmembrane PRO polypeptides (e.g. PRO183, PRO184,
PRO361 or PRO846) useful as targets for therapeutic intervention in
cancers (e.g. lung or breast cancers), or for diagnosing these cancers

Claim 12; Fig 99; 647pp; English.

The invention discloses isolated PRO secreted/transmembrane polypeptides
comprising a sequence without signal peptide and the nucleic acid
encoding them. The polypeptides can be used to raise antibodies that

CC specifically bind to the PRO polypeptide, for linking a bioactive
CC molecule to a cell expressing a PRO protein and for modulating at least
CC one biological activity of a cell. The PRO polypeptides or
CC polynucleotides are also useful as pharmaceuticals, diagnostics,
CC biosensors or bioreactors, for detecting or treating e.g. tumours in
CC mammals, e.g. humans, dogs, cats, cattle, horses, sheep, pigs, goats or
CC rabbits as targets for therapeutic intervention in certain cancers (e.g.
CC colon, lung or breast cancers) and diagnostic determination of the
CC presence of these cancers. The PRO polypeptides are also useful as
CC molecular weight markers or for chromosome identification. The PRO genes
CC are useful as hybridisation probes or for screening libraries of human
CC cDNA, genomic DNA or mRNA. The PRO genes may also be used in gene
CC therapy, particularly for replacing a defective gene. The sequences
CC presented in ABUS8900-ABUS9046 are the PRO polypeptides of the invention.

XX Sequence 119 AA;

Query Match 100.0%; Score 119; DB 24; Length 119;
Best Local Similarity 100.0%; Pred. No. 3.3e-110;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MKVLISLILLPLMLMSVSSSLNPGVARGHRRDQASRRWLQEGGCECKDWFLRAP 60
DB 1 MKVLISLILLPLMLMSVSSSLNPGVARGHRRDQASRRWLQEGGCECKDWFLRAP 60
QY 61 RRKFTVSGLPKQPCDHFKNVKTTRHORHRRKKNKSRACQQLKCOLRSFALPL 119
DB 61 RRKFTVSGLPKQPCDHFKNVKTTRHORHRRKKNKSRACQQLKCOLRSFALPL 119

RESULT 26

ABUS6005
ID ABUS6005 standard; Protein; 119 AA.

XX ABUS6005;

XX 26-MAR-2003 (first entry)

XX Human secreted/transmembrane protein, PRO842.

XX Human; secreted protein; transmembrane protein; PRO;
KW antarthritic; vulnary; tumour necrosis factor-alpha;
KW chondrocyte cell proliferation; chondrocyte cell differentiation;
KW tumour; adrenal tumour; lung tumour; colon tumour; breast tumour;
KW prostate tumour; rectal tumour; cervical tumour; liver tumour;
KW bone disorder; cartilage disorder; arthritis; sports injury.

XX Homo sapiens.

XX US2003022298-A1.

XX 30-JAN-2003.

XX 20-JUN-2002; 2002US-0176913.

XX 05-NOV-1997; 97WO-US20069.
PR 10-SEP-1998; 98WO-US18824.
PR 14-SEP-1998; 98WO-US19177.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 20-NOV-1998; 98WO-US24855.
PR 01-DEC-1998; 98WO-US25108.
PR 05-JAN-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 10-MAR-1999; 99WO-US05190.
PR 20-APR-1999; 99WO-US08615.
PR 14-MAY-1999; 99WO-US10733.
PR 02-JUN-1999; 99WO-US12252.
PR 01-SEP-1999; 99WO-US20111.
PR 08-SEP-1999; 99WO-US20594.
PR 13-SEP-1999; 99WO-US20944.
PR 15-SEP-1999; 99WO-US21090.

5-SEP-1999;	99WO-US21547.	PR	11-MAR-1998;	98US-077649P.
15-OCT-1999;	99WO-US23089.	PR	20-MAR-1998;	98US-078886P.
19-NOV-1999;	99WO-US28214.	PR	20-MAR-1998;	98US-078939P.
10-NOV-1999;	99WO-US28313.	PR	27-MAR-1998;	98US-079664P.
10-NOV-1999;	99WO-US28409.	PR	27-MAR-1998;	98US-079786P.
11-DEC-1999;	99WO-US28301.	PR	31-MAR-1998;	98US-080107P.
11-DEC-1999;	99WO-US28634.	PR	31-MAR-1998;	98US-080194P.
12-DEC-1999;	99WO-US28551.	PR	01-APR-1998;	98US-080327P.
12-DEC-1999;	99WO-US28564.	PR	01-APR-1998;	98US-080333P.
12-DEC-1999;	99WO-US28565.	PR	08-APR-1998;	98US-081043P.
6-DEC-1999;	99WO-US30095.	PR	08-APR-1998;	98US-081070P.
10-DEC-1999;	99WO-US30911.	PR	09-APR-1998;	98US-081195P.
10-DEC-1999;	99WO-US30999.	PR	15-APR-1998;	98US-081838P.
22-DEC-1999;	99WO-US30720.	PR	21-APR-1998;	98US-082568P.
10-DEC-1999;	99WO-US31243.	PR	21-APR-1998;	98US-082569P.
10-DEC-1999;	99WO-US31274.	PR	22-APR-1998;	98US-082704P.
35-JAN-2000;	2000WO-US00219.	PR	22-APR-1998;	98US-082797P.
16-JAN-2000;	2000WO-US00277.	PR	28-APR-1998;	98US-083222P.
16-JAN-2000;	2000WO-US00376.	PR	29-APR-1998;	98US-083495P.
11-FEB-2000;	2000WO-US03565.	PR	29-APR-1998;	98US-083496P.
18-FEB-2000;	2000WO-US04341.	PR	29-APR-1998;	98US-083499P.
18-FEB-2000;	2000WO-US04342.	PR	29-APR-1998;	98US-083559P.
24-FEB-2000;	2000WO-US04414.	PR	05-MAY-1998;	98US-084366P.
24-FEB-2000;	2000WO-US05004.	PR	06-MAY-1998;	98US-084414P.
31-MAR-2000;	2000WO-US05601.	PR	07-MAY-1998;	98US-084639P.
12-MAR-2000;	2000WO-US05841.	PR	07-MAY-1998;	98US-084640P.
10-MAR-2000;	2000WO-US06319.	PR	07-MAY-1998;	98US-084643P.
15-MAR-2000;	2000WO-US06884.	PR	15-MAY-1998;	98US-085579P.
21-MAR-2000;	2000WO-US07532.	PR	15-MAY-1998;	98US-085580P.
30-MAR-2000;	2000WO-US08439.	PR	15-MAY-1998;	98US-085582P.
17-MAY-2000;	2000WO-US13705.	PR	15-MAY-1998;	98US-085700P.
22-MAY-2000;	2000WO-US14042.	PR	18-MAY-1998;	98US-085702P.
30-MAY-2000;	2000WO-US14941.	PR	22-MAY-1998;	98US-086023P.
02-JUN-2000;	2000WO-US15264.	PR	22-MAY-1998;	98US-086352P.
28-JUL-2000;	2000WO-US20710.	PR	28-MAY-1998;	98US-086486P.
11-AUG-2000;	2000WO-US22031.	PR	28-MAY-1998;	98US-087098P.
23-AUG-2000;	2000WO-US23522.	PR	02-JUN-1998;	98US-087208P.
24-AUG-2000;	2000WO-US23328.	PR	02-JUN-1998;	98US-087609P.
08-NOV-2000;	2000WO-US03052.	PR	02-JUN-1998;	98US-087759P.
10-NOV-2000;	2000WO-US30873.	PR	03-JUN-1998;	98US-087759P.
01-DEC-2000;	2000WO-US32678.	PR	04-JUN-1998;	98US-088025P.
20-DEC-2000;	2000WO-US34956.	PR	04-JUN-1998;	98US-088028P.
28-FEB-2001;	2001WO-US06520.	PR	04-JUN-1998;	98US-088028P.
22-MAR-2001;	2001WO-US09552.	PR	04-JUN-1998;	98US-088029P.
25-MAY-2001;	2001WO-US17092.	PR	04-JUN-1998;	98US-088033P.
01-JUN-2001;	2001WO-US17800.	PR	05-JUN-1998;	98US-088326P.
20-JUN-2001;	2001WO-US19692.	PR	05-JUN-1998;	98US-088167P.
09-JUL-2001;	2001WO-US21066.	PR	05-JUN-1998;	98US-088202P.
29-AUG-2001;	2001WO-US21735.	PR	05-JUN-1998;	98US-088212P.
18-SEP-1997;	97US-059263P.	PR	05-JUN-1998;	98US-088217P.
18-SEP-1997;	97US-059266P.	PR	10-JUN-1998;	98US-088655P.
17-OCT-1997;	97US-062250P.	PR	10-JUN-1998;	98US-088722P.
21-OCT-1997;	97US-063486P.	PR	10-JUN-1998;	98US-088738P.
24-OCT-1997;	97US-063120P.	PR	10-JUN-1998;	98US-088740P.
28-OCT-1997;	97US-063121P.	PR	10-JUN-1998;	98US-088811P.
28-OCT-1997;	97US-063540P.	PR	11-JUN-1998;	98US-088824P.
28-OCT-1997;	97US-063541P.	PR	11-JUN-1998;	98US-088825P.
28-OCT-1997;	97US-063544P.	PR	11-JUN-1998;	98US-088861P.
29-OCT-1997;	97US-063564P.	PR	11-JUN-1998;	98US-088863P.
31-OCT-1997;	97US-063734P.	PR	11-JUN-1998;	98US-088876P.
31-OCT-1997;	97US-063870P.	PR	12-JUN-1998;	98US-089090P.
13-NOV-1997;	97US-065311P.	PR	16-JUN-1998;	98US-089105P.
21-NOV-1997;	97US-065120P.	PR	17-JUN-1998;	98US-089512P.
24-NOV-1997;	97US-066466P.	PR	17-JUN-1998;	98US-089538P.
24-NOV-1997;	97US-066772P.	PR	17-JUN-1998;	98US-089598P.
11-DEC-1997;	97US-069335P.	PR	18-JUN-1998;	98US-089653P.
12-DEC-1997;	97US-069425P.	PR	18-JUN-1998;	98US-089653P.
17-DEC-1997;	97US-069870P.	PR	19-JUN-1998;	98US-089908P.
18-DEC-1997;	97US-068017P.	PR	19-JUN-1998;	98US-089952P.
10-MAR-1998;	98US-077450P.	PR	22-JUN-1998;	98US-090246P.
11-MAR-1998;	98US-077632P.	PR	22-JUN-1998;	98US-090252P.
		PR	22-JUN-1998;	98US-090254P.
		PR	24-JUN-1998;	98US-090429P.
		PR	24-JUN-1998;	98US-090435P.

24-JUN-1998; 98US-090444P.
24-JUN-1998; 98US-090461P.
24-JUN-1998; 98US-090535P.
24-JUN-1998; 98US-090540P.
25-JUN-1998; 98US-090676P.
25-JUN-1998; 98US-090678P.
25-JUN-1998; 98US-090688P.
25-JUN-1998; 98US-090690P.
25-JUN-1998; 98US-090694P.
25-JUN-1998; 98US-090695P.
25-JUN-1998; 98US-090696P.
25-JUN-1998; 98US-090862P.
26-JUN-1998; 98US-090863P.

ary Match 100.0%; Score 119; DB 24; Length 119;
st Local Similarity 100.0%; Pred. No. 3.3e-110;
tches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 MKVLISLLLLLPLMSVSSSLNPGVARGHRDGRGASRRWLQEGGQCECKDWFRLAP 60
1 MKVLISLLLLLPLMSVSSSLNPGVARGHRDGRGASRRWLQEGGQCECKDWFRLAP 60

61 RKKFTVSLPKKQPCDHFHFGNVKTRHQRHHRKPNKHGRACQFLKQQLRSFALPL 119
61 RKKFTVSLPKKQPCDHFHFGNVKTRHQRHHRKPNKHGRACQFLKQQLRSFALPL 119

LT 27
7000
ABU57000 standard; Protein; 119 AA.
ABU57000;

04-APR-2003 (first entry)
Human PRO polypeptide #70.

Human; PRO; tumour necrosis factor-alpha; blood; cancer;
chondrocyte cell; tumour; adrenal tumour; lung; colon; breast; prostate;
kidney; rectum; cervix; liver; bone disorder; cartilage disorder;
arthritis; sports injury; Genetic disorder; antiarthritic; vulnerary.

Homo sapiens.
US2003027280-A1.

06-FEB-2003.

20-JUN-2002; 2002US-0176993.

16-SEP-1998; 98WO-US19330.
07-OCT-1998; 98WO-US21141.
01-DEC-1998; 98WO-US25108.
08-MAR-1999; 99WO-US05028.
14-MAY-1999; 99WO-US10733.
02-JUN-1999; 99WO-US12252.
01-SEP-1999; 99WO-US20111.
15-SEP-1999; 99WO-US21090.
01-DEC-1999; 99WO-US28301.
02-DEC-1999; 99WO-US28351.
30-DEC-1999; 99WO-US31274.
05-JAN-2000; 2000WO-US00219.
18-FEB-2000; 2000WO-US04341.
18-FEB-2000; 2000WO-US04342.
22-FEB-2000; 2000WO-US04414.
24-FEB-2000; 2000WO-US05004.
01-MAR-2000; 2000WO-US05601.
02-MAR-2000; 2000WO-US05841.
15-MAR-2000; 2000WO-US06884.
30-MAR-2000; 2000WO-US08439.
17-MAY-2000; 2000WO-US13705.
22-MAY-2000; 2000WO-US14042.
30-MAY-2000; 2000WO-US14941.

02-JUN-2000; 2000WO-US15264.
28-JUL-2000; 2000WO-US20710.
24-AUG-2000; 2000WO-US23328.
08-NOV-2000; 2000WO-US30952.
01-DEC-2000; 2000WO-US32678.
20-DEC-2000; 2000WO-US34956.
28-FEB-2001; 2001WO-US06520.
01-JUN-2001; 2001WO-US17800.
20-JUN-2001; 2001WO-US19692.
29-JUL-2001; 2001WO-US21066.
09-AUG-2001; 2001WO-US21735.
29-AUG-2001; 2001WO-US27099.
18-SEP-1997; 97US-059263P.
18-SEP-1997; 97US-059265P.
17-OCT-1997; 97US-062250P.
21-OCT-1997; 97US-063486P.
24-OCT-1997; 97US-063120P.
24-OCT-1997; 97US-063121P.
28-OCT-1997; 97US-063540P.
28-OCT-1997; 97US-063541P.
28-OCT-1997; 97US-063544P.
28-OCT-1997; 97US-063564P.
29-OCT-1997; 97US-063734P.
31-OCT-1997; 97US-063870P.
31-OCT-1997; 97US-064103P.
13-NOV-1997; 97US-065311P.
21-NOV-1997; 97US-066120P.
21-NOV-1997; 97US-066466P.
24-NOV-1997; 97US-066772P.
11-DEC-1997; 97US-069335P.
12-DEC-1997; 97US-069425P.
17-DEC-1997; 97US-069870P.
18-DEC-1997; 97US-068017P.
10-MAR-1998; 98US-077450P.
11-MAR-1998; 98US-077632P.
11-MAR-1998; 98US-077649P.
20-MAR-1998; 98US-078886P.
20-MAR-1998; 98US-078939P.
27-MAR-1998; 98US-079664P.
27-MAR-1998; 98US-079786P.
31-MAR-1998; 98US-080107P.
31-MAR-1998; 98US-080194P.
01-APR-1998; 98US-080327P.
01-APR-1998; 98US-080333P.
08-APR-1998; 98US-081043P.
08-APR-1998; 98US-081070P.
09-APR-1998; 98US-081195P.
21-APR-1998; 98US-081838P.
21-APR-1998; 98US-082568P.
22-APR-1998; 98US-082569P.
22-APR-1998; 98US-082704P.
22-APR-1998; 98US-082797P.
28-APR-1998; 98US-083322P.
29-APR-1998; 98US-083495P.
29-APR-1998; 98US-083496P.
29-APR-1998; 98US-083499P.
29-APR-1998; 98US-083559P.
05-MAY-1998; 98US-084366P.
06-MAY-1998; 98US-084414P.
07-MAY-1998; 98US-084639P.
07-MAY-1998; 98US-084640P.
07-MAY-1998; 98US-084643P.
15-MAY-1998; 98US-085579P.
15-MAY-1998; 98US-085580P.
15-MAY-1998; 98US-085582P.
15-MAY-1998; 98US-085700P.
18-MAY-1998; 98US-086023P.
22-MAY-1998; 98US-086392P.
22-MAY-1998; 98US-086486P.
28-MAY-1998; 98US-087098P.
28-MAY-1998; 98US-087208P.
02-JUN-1998; 98US-087609P.
02-JUN-1998; 98US-087759P.

```

3-JUN-1998; 98US-087827P.
4-JUN-1998; 98US-088025P.
4-JUN-1998; 98US-088028P.
4-JUN-1998; 98US-088029P.
4-JUN-1998; 98US-088033P.
4-JUN-1998; 98US-088326P.
5-JUN-1998; 98US-088167P.
5-JUN-1998; 98US-088202P.
5-JUN-1998; 98US-088212P.
5-JUN-1998; 98US-088217P.
9-JUN-1998; 98US-088655P.
0-JUN-1998; 98US-088722P.
0-JUN-1998; 98US-088738P.
0-JUN-1998; 98US-088740P.
0-JUN-1998; 98US-088811P.
0-JUN-1998; 98US-088824P.
0-JUN-1998; 98US-088825P.
0-JUN-1998; 98US-088826P.
1-JUN-1998; 98US-088861P.
1-JUN-1998; 98US-088863P.
1-JUN-1998; 98US-088876P.
2-JUN-1998; 98US-089090P.
2-JUN-1998; 98US-089105P.
6-JUN-1998; 98US-089512P.
6-JUN-1998; 98US-089514P.
7-JUN-1998; 98US-089538P.
7-JUN-1998; 98US-089598P.
7-JUN-1998; 98US-089653P.
8-JUN-1998; 98US-089908P.
9-JUN-1998; 98US-089952P.
12-JUN-1998; 98US-090246P.
12-JUN-1998; 98US-090252P.
12-JUN-1998; 98US-090254P.
14-JUN-1998; 98US-090429P.
14-JUN-1998; 98US-090435P.
14-JUN-1998; 98US-090444P.
14-JUN-1998; 98US-090461P.
14-JUN-1998; 98US-090535P.
14-JUN-1998; 98US-090540P.
25-JUN-1998; 98US-090676P.
25-JUN-1998; 98US-090678P.
25-JUN-1998; 98US-090688P.
25-JUN-1998; 98US-090690P.
25-JUN-1998; 98US-090694P.
25-JUN-1998; 98US-090695P.
25-JUN-1998; 98US-090696P.
26-JUN-1998; 98US-090862P.
26-JUN-1998; 98US-090863P.
26-JUN-1998; 98US-091010P.
01-JUL-1998; 98US-091359P.
01-JUL-1998; 98US-091544P.
02-JUL-1998; 98US-091478P.
02-JUL-1998; 98US-091486P.
02-JUL-1998; 98US-091626P.
02-JUL-1998; 98US-091628P.
02-JUL-1998; 98US-091632P.
02-JUL-1998; 98US-091633P.
04-AUG-1998; 98US-095282P.
10-AUG-1998; 98US-095998P.
10-AUG-1998; 98US-096012P.
17-AUG-1998; 98US-096757P.
17-AUG-1998; 98US-096766P.
17-AUG-1998; 98US-096867P.
17-AUG-1998; 98US-096891P.
17-AUG-1998; 98US-096897P.
18-AUG-1998; 98US-096949P.
18-AUG-1998; 98US-096959P.
18-AUG-1998; 98US-097022P.
26-AUG-1998; 98US-097952P.
26-AUG-1998; 98US-097954P.
26-AUG-1998; 98US-097955P.
26-AUG-1998; 98US-097971P.
26-AUG-1998; 98US-097974P.

26-AUG-1998; 98US-098014P.
01-SEP-1998; 98US-098716P.
01-SEP-1998; 98US-098723P.
02-SEP-1998; 98US-098803P.
02-SEP-1998; 98US-098821P.
02-SEP-1998; 98US-098843P.
09-SEP-1998; 98US-099602P.
10-SEP-1998; 98US-099741P.
10-SEP-1998; 98US-099754P.
10-SEP-1998; 98US-099763P.

Query Match 100.0%; Score 119; DB 24; Length 119;
Best Local Similarity 100.0%; Pred No. 3.3e-110;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MKVLISSLLLLPLMLMSVSSSLNPGVARGHHRDRCQARRMLQEGGQCECKQWFLRAP 60
DB 1 MKVLISSLLLLPLMLMSVSSSLNPGVARGHHRDRCQARRMLQEGGQCECKQWFLRAP 60
QY 61 RRKEMTVSGLPKQPCDHFKNVKKTRHORHRRKKNHSHRACQOFLKQQLRSFALPL 119
DB 61 RRKEMTVSGLPKQPCDHFKNVKKTRHORHRRKKNHSHRACQOFLKQQLRSFALPL 119

RESULT 28
ABU13897
ID ABU13897 standard; Protein; 119 AA.
XX
AC ABU13897;
XX
DT 26-FEB-2003 (first entry)
XX
DE Human PRO842 polypeptide.
XX
KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW genetic disorder; antibacterial; immunosuppressive.
OS Homo sapiens.
XX
PN US2002103125-A1.
XX
PD 01-AUG-2002.
XX
PF 20-NOV-2001; 2001US-0989731.
XX
PR 05-NOV-1997; 97WO-US20069.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 05-JAN-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 02-JUN-1999; 99WO-US12552.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 16-DEC-1999; 99WO-US28634.
PR 20-DEC-1999; 99WO-US30095.
PR 06-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 15-MAY-2000; 2000WO-US13358.

```

17-MAY-2000; 2000WO-US13705.
22-MAY-2000; 2000WO-US14042.
30-MAY-2000; 2000WO-US14941.
02-JUN-2000; 2000WO-US15264.
28-JUL-2000; 2000WO-US20710.
11-AUG-2000; 2000WO-US22031.
23-AUG-2000; 2000WO-US23522.
24-AUG-2000; 2000WO-US23328.
08-NOV-2000; 2000WO-US30952.
01-DEC-2000; 2000WO-US32678.
28-FEB-2001; 2001WO-US06520.
01-JUN-2001; 2001WO-US17800.
20-JUN-2001; 2001WO-US19692.
29-JUN-2001; 2001WO-US21066.
09-JUL-2001; 2001WO-US21735.
16-JUN-1997; 97US-04978P.
17-OCT-1997; 97US-062250P.
12-NOV-1997; 97US-065186P.
13-NOV-1997; 97US-065311P.
24-NOV-1997; 97US-066770P.
25-FEB-1998; 98US-075945P.
20-MAR-1998; 98US-078910P.
28-APR-1998; 98US-083222P.
07-MAY-1998; 98US-084600P.
28-MAY-1998; 98US-087106P.
02-JUN-1998; 98US-087607P.
02-JUN-1998; 98US-087609P.
03-JUN-1998; 98US-087759P.
04-JUN-1998; 98US-088021P.
04-JUN-1998; 98US-088025P.
04-JUN-1998; 98US-088026P.
04-JUN-1998; 98US-088028P.
04-JUN-1998; 98US-088029P.
04-JUN-1998; 98US-088030P.
04-JUN-1998; 98US-088033P.
04-JUN-1998; 98US-088326P.
05-JUN-1998; 98US-088167P.
05-JUN-1998; 98US-088202P.
05-JUN-1998; 98US-088212P.
05-JUN-1998; 98US-088217P.
09-JUN-1998; 98US-088655P.
10-JUN-1998; 98US-088734P.
10-JUN-1998; 98US-088738P.
10-JUN-1998; 98US-088742P.
10-JUN-1998; 98US-088810P.
10-JUN-1998; 98US-088824P.
10-JUN-1998; 98US-088826P.
11-JUN-1998; 98US-088858P.
11-JUN-1998; 98US-088861P.
11-JUN-1998; 98US-088876P.
12-JUN-1998; 98US-089105P.
12-JUN-1998; 98US-089440P.
16-JUN-1998; 98US-089512P.
16-JUN-1998; 98US-089514P.
17-JUN-1998; 98US-089532P.
17-JUN-1998; 98US-089538P.
17-JUN-1998; 98US-089598P.
17-JUN-1998; 98US-089599P.
17-JUN-1998; 98US-089600P.
17-JUN-1998; 98US-089653P.
18-JUN-1998; 98US-089801P.
18-JUN-1998; 98US-089907P.
18-JUN-1998; 98US-089908P.
28-AUG-2001; 2001US-0941992.

(GETH) GENENTECH LTD.

Askenazi AJ, Baker KP, Botstein D, Deenoyers L, Eaton DL;
Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
Grimaldi JC, Gurley AL, Kijavini IJ, Napier MA, Pan J, Paoni NF;
Roy MA, Stewart TA, Tamas D, Watanabe CK, Williams PM, Wood WI;
Zhang Z;

XX MPI; 2003-102117/09.
DR N-PSDB; ABX64055.
XX Novel secreted and transmembrane polypeptide for modulating biological
PT activity of cell expressing the polypeptide, identifying agonists or
PT antagonists of polypeptide, and as molecular weight markers -
XX Claim 12; Fig 99; 649pp; English.
XX The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The
CC PRO polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides are useful for detecting other PRO polypeptides, for
CC linking bioactive molecules to cells expressing PRO polypeptides,
CC for modulating biological activities of cells expressing PRO
CC polypeptides, and for identifying agonists or antagonists.
CC The polynucleotide sequences encoding PRO polypeptides are useful as
CC hybridisation probes, in chromosome and gene mapping, in the generation
CC of antisense RNA and DNA, in the preparation of PRO polypeptides, for
CC generating transgenic animals or knockout animals, to construct
CC hybridisation probes for mapping the gene which encodes the PRO
CC polypeptide, and for the genetic analysis of individuals with genetic
CC disorders, in gene therapy, for chromosome identification, as
CC chromosome markers, and for generating probes for PCR, Northern
CC analysis, Southern analysis and Western analysis. ABU13860-ABU14006
CC represent the human PRO polypeptides of the invention.
CC Note: The sequence data for this patent was obtained in electronic
CC format directly from the USPTO web site at
CC seqdata.uspto.gov/psipsdIDentry.html.
XX Sequence 119 AA;
SQ
Query Match 100.0%; Score 119; DB 24; Length 119;
Best Local Similarity 100.0%; Pred. No. 3.3e-110; Indels 0; Gaps 0;
Matches 119; Conservative 0; Mismatches 0;
QY 1 MKVLISILLILLPLMLSMVSSSLNPGVARGHRRDQASRRWLQEGGQCECKDWFLRAP 60
Db 1 MKVLISILLILLPLMLSMVSSSLNPGVARGHRRDQASRRWLQEGGQCECKDWFLRAP 60
QY 61 RRKFTVSGLPKQCPCDHFPGKGVKTRHQRHRRKPKHRSRACQQLKOCQLRSFALPL 119
Db 61 RRKFTVSGLPKQCPCDHFPGKGVKTRHQRHRRKPKHRSRACQQLKOCQLRSFALPL 119
RESULT 29
ABU10579
ID ABU10579 standard; Protein; 119 AA.
XX AC ABU10579;
XX DT 03-FEB-2003 (first entry)
XX DE Human secreted/transmembrane protein #70.
XX KW Human; secreted and transmembrane protein; blood;
KW tumour necrosis factor-alpha; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour; adrenal tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; bone disorder; cartilage disorder;
KW arthritis; sports injury.
XX OS Homo sapiens.
XX PN US2002127584-A1.
XX PD 12-SEP-2002.
XX PF 15-JAN-2002; 2002US-0052586.
XX PR 16-SEP-1998; 98WO-US19330.
PR 07-OCT-1998; 98WO-US21141.

11-DEC-1998; 98WO-US25108.
16-JAN-1999; 2000WO-US00219.
18-MAR-1999; 99WO-US05028.
14-MAY-1999; 99WO-US10733.
12-JUN-1999; 99WO-US12252.
11-SEP-1999; 99WO-US20111.
15-SEP-1999; 99WO-US21090.
11-DEC-1998; 99WO-US28301.
12-DEC-1999; 99WO-US28551.
10-DEC-1999; 99WO-US31274.
18-FEB-2000; 2000WO-US04341.
18-FEB-2000; 2000WO-US04342.
22-FEB-2000; 2000WO-US04414.
24-FEB-2000; 2000WO-US05004.
11-MAR-2000; 2000WO-US05601.
12-MAR-2000; 2000WO-US05841.
15-MAR-2000; 2000WO-US06884.
10-MAR-2000; 2000WO-US08439.
17-MAY-2000; 2000WO-US13705.
22-MAY-2000; 2000WO-US14042.
30-MAY-2000; 2000WO-US14941.
22-JUN-2000; 2000WO-US15264.
28-JUL-2000; 2000WO-US20710.
24-AUG-2000; 2000WO-US23328.
08-NOV-2000; 2000WO-US30952.
01-DEC-2000; 2000WO-US32678.
20-DEC-2000; 2000WO-US34956.
28-FEB-2001; 2001WO-US06520.
01-JUN-2001; 2001WO-US17800.
20-JUN-2001; 2001WO-US18922.
29-JUN-2001; 2001WO-US21066.
09-JUL-2001; 2001WO-US21735.
29-AUG-2001; 2001WO-US27099.
18-SEP-1997; 97US-059266P.
18-SEP-1997; 97US-059266P.
17-OCT-1997; 97US-062250P.
21-OCT-1997; 97US-063486P.
24-OCT-1997; 97US-063120P.
24-OCT-1997; 97US-063121P.
28-OCT-1997; 97US-063540P.
28-OCT-1997; 97US-063541P.
28-OCT-1997; 97US-063544P.
28-OCT-1997; 97US-063564P.
29-OCT-1997; 97US-063734P.
31-OCT-1997; 97US-063870P.
31-OCT-1997; 97US-064103P.
13-NOV-1997; 97US-065311P.
21-NOV-1997; 97US-066120P.
24-NOV-1997; 97US-066466P.
24-NOV-1997; 97US-066772P.
11-DEC-1997; 97US-069333P.
12-DEC-1997; 97US-069423P.
17-DEC-1997; 97US-069870P.
18-DEC-1997; 97US-068017P.
10-MAR-1998; 98US-077450P.
11-MAR-1998; 98US-077632P.
11-MAR-1998; 98US-077649P.
11-MAR-1998; 98US-078886P.
20-MAR-1998; 98US-078939P.
20-MAR-1998; 98US-079664P.
27-MAR-1998; 98US-079786P.
31-MAR-1998; 98US-080107P.
31-MAR-1998; 98US-080194P.
01-APR-1998; 98US-080327P.
01-APR-1998; 98US-080333P.
08-APR-1998; 98US-081049P.
08-APR-1998; 98US-081070P.
09-APR-1998; 98US-081195P.
15-APR-1998; 98US-081838P.
21-APR-1998; 98US-082568P.
21-APR-1998; 98US-082569P.
22-APR-1998; 98US-082704P.
22-APR-1998; 98US-082797P.

PR 28-APR-1998; 98US-083322P.
PR 29-APR-1998; 98US-083495P.
PR 29-APR-1998; 98US-083496P.
PR 29-APR-1998; 98US-083499P.
PR 29-APR-1998; 98US-083559P.
PR 05-MAY-1998; 98US-084366P.
PR 06-MAY-1998; 98US-084414P.
PR 07-MAY-1998; 98US-084639P.
PR 07-MAY-1998; 98US-084640P.
PR 07-MAY-1998; 98US-084643P.
XX
XX (GETH) GENENTECH INC.
PA Baker KP, Chen J, Desnoyers L, Goddard A, Godowski PJ, Gurney AL;
XX Pan J, Smith V, Watanabe CK, Wood WI, Zhang Z;
XX WPI: 2003-066893/06.
XX N-PSDB; ABX16655.
XX Novel isolated PRO polypeptides e.g., PRO1079, PRO827, PRO791, PRO1131,
PT PRO316, PRO1183, PRO1343, PRO1760, PRO1567 or PRO4333, useful for
XX stimulating release of tumor necrosis factor-alpha from human blood -
XX Claim 11; Fig 140; 701pp; English.
PS The invention relates to an isolated PRO polypeptide comprising at least
XX 80% sequence identity to the protein sequences appearing as ABU10510-
CC ABU10814 (including a version lacking its associated signal peptide, or
CC an isolated extracellular domain of a PRO polypeptide with or without
CC its associated signal peptide. Also included are the nucleic acids
CC encoding the PRO proteins (being secreted and transmembrane proteins)
CC appearing as ABX15586-ABX16590, PRO expression vectors, host cells,
CC chimeric PRO fusion proteins, an anti-PRO antibody and a PRO
CC derived oligonucleotide sequence. The PRO polypeptides are useful for
CC stimulating release of tumor necrosis factor-alpha from human blood.
CC The PRO polypeptide PRO6029 is useful for stimulating proliferation or
CC differentiation of chondrocyte cells. The PRO polypeptides as specified
CC in the specification and having differential expression in tumour cells,
CC are useful for detecting presence of tumour in a mammal (such as adrenal
CC tumour, lung tumour, colon tumour, breast tumour, prostate tumour, rectal
CC tumour, cervical tumour or liver tumour. The PRO polypeptide PRO6029 is
CC useful for treating various bone and/or cartilage disorders such as
CC arthritis, and sports injuries. The PRO polypeptides are useful for
CC screening compounds to identify ant/agonists. PRO nucleic acids
CC are useful as hybridisation probes, in chromosome and gene mapping,
CC in the generation of anti-sense RNA and DNA, for the preparation of PRO
CC polypeptides and for generating knock-out animals. The present
XX sequence represents a PRO polypeptide.
SQ Sequence 119 AA;
Query Match 100.0%; Score 119; DB 24; Length 119;
Best Local Similarity 100.0%; Pred. No. 3.3e-110;
Matches 119; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRRDQASRRWLQGGQCECKDWFLRAP 60
Db 1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRRDQASRRWLQGGQCECKDWFLRAP 60
Qy 61 RRKFTVSGLPKQCPDHFKGNVKKTRHQHRRKPKHSHRACQQLKQQLRSFALPL 119
Db 61 RRKFTVSGLPKQCPDHFKGNVKKTRHQHRRKPKHSHRACQQLKQQLRSFALPL 119
RESULT 30
ABU10852
ID ABU10852 standard; protein; 119 AA.
XX
XX ABU10852;
AC
XX 04-FEB-2003 (first entry)
DT
XX Human PRO polypeptide #38.
DE

Human; PRO; secreted polypeptide; transmembrane polypeptide; toxin; radiolabel; cell death; gene mapping; chromosome mapping; protein electrophoresis; Genetic disorder; immunosuppressive; cytostatic; antibacterial.

Homo sapiens.

US2002123463-A1.

05-SEP-2002.

19-NOV-2001; 2001US-0989732.

05-NOV-1997; 97WO-US20069.

16-SEP-1998; 98WO-US19330.

17-SEP-1998; 98WO-US19437.

07-OCT-1998; 98WO-US21141.

01-DEC-1998; 98WO-US25108.

05-JAN-1999; 99WO-US00106.

08-MAR-1999; 99WO-US05028.

02-JUN-1999; 99WO-US12252.

15-SEP-1999; 99WO-US21090.

15-SEP-1999; 99WO-US21547.

30-NOV-1999; 99WO-US28313.

01-DEC-1999; 99WO-US28301.

01-DEC-1999; 99WO-US28634.

16-DEC-1999; 99WO-US30095.

20-DEC-1999; 99WO-US30911.

06-JAN-2000; 2000WO-US00219.

06-JAN-2000; 2000WO-US00376.

11-FEB-2000; 2000WO-US03565.

18-FEB-2000; 2000WO-US04341.

22-FEB-2000; 2000WO-US04414.

24-FEB-2000; 2000WO-US04914.

24-FEB-2000; 2000WO-US05004.

02-MAR-2000; 2000WO-US05841.

10-MAR-2000; 2000WO-US06319.

15-MAR-2000; 2000WO-US06884.

20-MAR-2000; 2000WO-US07377.

30-MAR-2000; 2000WO-US08439.

15-MAY-2000; 2000WO-US33358.

17-MAY-2000; 2000WO-US31705.

22-MAY-2000; 2000WO-US14042.

30-MAY-2000; 2000WO-US14941.

02-JUN-2000; 2000WO-US15264.

28-JUL-2000; 2000WO-US20710.

11-AUG-2000; 2000WO-US22031.

23-AUG-2000; 2000WO-US23522.

24-AUG-2000; 2000WO-US33328.

08-NOV-2000; 2000WO-US30952.

01-DEC-2000; 2000WO-US32678.

28-FEB-2001; 2001WO-US06520.

01-JUN-2001; 2001WO-US17800.

20-JUN-2001; 2001WO-US19692.

29-JUN-2001; 2001WO-US21066.

09-JUL-2001; 2001WO-US21735.

16-JUN-1997; 97US-048787P.

17-OCT-1997; 97US-062250P.

12-NOV-1997; 97US-065186P.

13-NOV-1997; 97US-065311P.

24-NOV-1997; 97US-066770P.

25-FEB-1998; 98US-075945P.

20-MAR-1998; 98US-078910P.

28-APR-1998; 98US-083322P.

07-MAY-1998; 98US-084600P.

28-MAY-1998; 98US-087106P.

02-JUN-1998; 98US-087607P.

02-JUN-1998; 98US-087609P.

03-JUN-1998; 98US-087759P.

03-JUN-1998; 98US-087827P.

04-JUN-1998; 98US-088021P.

PR 04-JUN-1998; 98US-088026P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088030P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088734P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088742P.
PR 10-JUN-1998; 98US-088810P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088828P.
PR 11-JUN-1998; 98US-088858P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089440P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089532P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089599P.
PR 17-JUN-1998; 98US-089600P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089801P.
PR 18-JUN-1998; 98US-089907P.
PR 18-JUN-1998; 98US-089908P.
PR 28-AUG-2001; 2001US-0941992.

(GETH) GENENTECH INC.

Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Klijavan IJ, Napier MA, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI, Zhang Z;

WPI; 2003-066810/06.

N-PSDB; ABX17019.

Novel secreted and transmembrane polypeptide for modulating biological activity of cell expressing the polypeptide, identifying agonists or antagonists of polypeptide, and as molecular weight markers

Claim 12, Fig 99, 655pp; English.

The invention relates to a secreted and transmembrane polypeptide, termed PRO polypeptide, and the polynucleotide encoding it. The polypeptide is useful for detecting PRO polypeptides and for linking a bioactive molecule to a cell expressing the above polypeptides, where the bioactive molecule is a toxin, radiolabel or an antibody. The bioactive material causes the death of the cell. The polypeptide is useful for identifying agonists or antagonists of the PRO polypeptide, for preparing variants of PRO, as a molecular weight marker for protein electrophoresis purposes and the PRO polynucleotide is useful for recombinantly expressing those markers. The polynucleotide is also useful as a hybridisation probe, in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents to construct hybridisation probes for mapping the gene which encodes PRO and for the genetic analysis of individuals with genetic disorders, in gene therapy, for chromosome identification, as a chromosome marker and for generating probes for PCR, Northern analysis, Southern analysis and Western analysis. This sequence represents a human PRO polypeptide of the invention.

XX

```
Sequence 119 AA;
  Local Match 100.0%; Score 119; DB 24; Length 119;
  Local Similarity 100.0%; Pred. No. 3.3e-110;
  Mismatches 0; Indels 0; Gaps 0;
  Conserved 0;
1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDRGQASRRWLOEGGCECKDWFLRAP 60
1 MKVLISLLLLPLMLMSVSSSLNPGVARGHRDRGQASRRWLOEGGCECKDWFLRAP 60
61 RRFKFTVSGLPKKQCPDHFKNVKKTRHQRHHRKPNKHSRACQFLKQCLRSFALPL 119
61 RRFKFTVSGLPKKQCPDHFKNVKKTRHQRHHRKPNKHSRACQFLKQCLRSFALPL 119

Completed: February 19, 2004, 18:29:22
Time : 46 secs
```